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ABSTRACT
CONFORMATIONAL DYNAMICS LEADING TO ACTIVATION OF THE
TRANSGLUTAMINASE FACTOR XIII
Richard Tatum Woofter II
16 December 2011
One of the last events that occurs during blood coagulation, a process
taken for granted on a daily basis, involves Factor XIII (FXIII) cross-linking fibrin
monomers to form an insoluble clot. In plasma, FXIII-A2 is not active and exists
as the heterotetramer FXIII-A2B2. Through the utilization of hydrogen deuterium exchange (HDX) coupled with Matrix Assisted Laser Desorption
ionization - Time of Flight - Mass Spectrometry (MALDI-TOF-MS), it was
determined that FXIII-A2 becomes nearly uniformly protected when bound to
FXIII-B2 and the FXIII-A2

~-barrels

playa major role in heterotetramer formation.

After dissociation from FXIII-B2, FXIII-A2 has the ability to become
activated in the presence of Ca 2+. The regions/residues of FXIII-A2 Ca 2+ affects
during activation were identified using HDX. It is debated whether FXIII-A2
undergoes an open conformation during activation. Transglutaminase 2 (TG2)
has been observed crystallographically in an open conformation. HDX was
utilized to compare the conformational dynamics of Transglutaminase 2 in
solution to that of FXIII-A2. The increase in exposure between the catalytic core
and

~-barrels

of TG2 yields evidence of an open conformation. A structural
vi

comparison of FXIII-A2 and TG2 identified steric hinderance within the A2 dimer
that could thwart a similar conformational change.
Once activated physiologically, FXIII-A2 is solely responsible for forming
the cross-links between fibrin monomers. The aC (233 - 425) region of fibrin
contains three reactive Gin residues and acts as a substrate for FXIII. Fibrin aC
(233 - 425) was expressed and its structure investigated via 15N-HSQC when in
solution with FXIII-A2.
The integral role of FXIII-A2 in the coagulation cascade leads to a dire
need for investigating its conformational dynamics during activation. The
research herein provides a stronger knowledge of FXIII-A2 structural changes
during activation and outlines FXIII-A2 interactions with 8 2 and the fibrin aC
domain. This progress in understanding FXIII-A2 dynamics could lead to
improved treatments for excessive bleeding and thrombosis.
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CHAPTER I
INTRODUCTION

Blood Coagulation Overview
The highway system that transports nutrients to all cells within the body
and aids in eliminating cellular waste is referred to as the circulatory system. The
circulatory system involves many organ systems working in harmony with one
another. The organ that acts as the carrier for all the nutrients, amino acids,
hormones and cellular waste is blood (1). If there is a breach in the vasculature
there needs to be processes in place which quickly and efficiently close the
breach while not allowing for any disturbance in the flow of blood (nutrients) to
cells throughout the body. Haemostasis ('hemo'

=blood + 'stasis' =stagnation),

the process of stopping blood flow in damaged tissue, starts with
vasoconstriction to slow the flow of blood to the damaged area. This
physiological process can also be assisted by external pressure on wounded
tissue. Following vasoconstriction, platelets are recruited to the damaged tissue
to form a plug. As the platelets aggregate, tissue factors signal the coagulation
cascade which ultimately concludes in a soluble fibrin clot being crosslinked by
factor XIII (FXIII) to form an insoluble clot (1) .
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Historically it was believed
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Figure 1: The conventional V-shaped cascade
model of coagulation. This model initiates via the
Intrinsic (contact factor) pathway or the extrinsic
(tissue factor) pathway. This diagram was adapted
from a poster distributed by Enzyme Research
Laboratories, South Bend, IN.

identity and function of the procoagulant enzymes. The early models involved
the familiar Y -shaped scheme (Figure 1 or for more detail Appendix A) where the
"intrinsic" and "extrinsic" pathways converged in a common pathway with the
production of Factor Xa After several decades of discoveries, questions started
to arise concerning the independent nature of the intrinsic and extrinsic
pathways. One such question being, why do patients with a deficiency of FVIII
and FIX (see appendix B for coagulation enzyme abbreviations) in the "intrinsic"
pathway contract hemophilia A and B respectively when they still have an intact
"extrinsic" pathway(5). Hoffman and Monroe have since worked to develop a
model in which coagulation is mediated by the cell surfaces where they occur.
They propose a model that incorporates three overlapping stages: 1- initiation,
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occurring on tissue factor baring cells; 2-amplification, occurs when platelets and
cofactors become activated prior to thrombin production; and 3- propagation,
where large amounts of thrombin are generated on the platelet surface (6).
Initiation

Tissue factor (TF) is an integral membrane protein that plays the role of
initiator in coagulation in vivo. As a membrane bound protein, TF remains
localized to the cell in which it was synthesized and these cells are generally
located outside the vasculature (7). Once there is a breach in the vessel, blood
will come into contact with the TF-bearing extravascular cells. FVII is easily
activated by coagulation and non-coagulation proteases and rapidly binds to
cellular TF. The FVlla-TF complex then goes on to further activate more FVII as
well as both FX and FIX. The FX that is activated by the FVIIA-TF complex is
quickly degraded if it leaves the cell surface, but when it remains within the
confines of the forming thrombus, it can combine with FVa to produce thrombin
which will aid in activating platelets and FVIII during amplification (8).
Amplification

The next step is to amplify the coagulation response that was just initiated.
The damage to the endothelium that initiated the response also allows platelets
to come in contact with TF-bearing cells. The thrombin that was produced during
the last stages of initiation is then utilized to enhance platelet adhesion and
activation (9). Thrombin also assists in preparing for procoagulant activity by
activating FV, FVIII, and FXI (8).
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A) Initiation

B) Amplification

let Adhesion

Figure 2: The Cell-Based Model of Hemostasis. In the cell based model, several cell surfaces are utilized in
during the series of events that lead to a fibrin clot. (A) During the Initiation phase TF-bearing cells become
exposed to plasma after injury and FIXa and lIa are released and diffuse to the platelet surface. (8) During
Amplification the lIa released on the TF-bearing surface serves to activate the platelets and FXI as well as
release vWF yielding FVllla. (C) During Propagation several of the enzymes that were activated earlier
assemble on the surface of the activated platelet. FIXa/FVlla form the tenase which aid in FXa formation .
FXa/FVa then form prothrombinase which results in the burst of lIa. lIa then goes on to cleave fibrinogen and
activate FXIII which crosslinks the fibrin to form an insoluble clot. Figure adapted from cell-based hemostasis
models (2, 6) .

Thrombin continues its action by activating platelets through the utilization
of their protease-activated receptors (PAR) (10) . FV is released from platelets
and subsequently activated by thrombin . Some of the thrombin remains on the
surface of the platelet and is available for cleaving other coagulation enzymes.
von Willebrand factor (vWF)/FVIII circulate together and when bound to the
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platelet surface, thrombin activates the FVIII through the release of vWF (11).
The amplification process has now produced activated platelets with activated
cofactors such as FVa, FVllla and FXla on their surfaces; therefore, propagation
is ready to commence.
Propagation

The FIXa and FVllla that were activated during initiation and propagation
respectively are now poised to form the intrinsic tenase complex on the surface
of activated platelets. Once FIXa diffuses from the TF-bearing cell to the platelet
these complexes begin to form. In addition to FIXa diffusing from the
neighboring TF-bearing cell, it can also be activated on the platelet surface by
FXla (12). The tenase complexes then continue the coagulation processes by
activating FX on the platelet surface where it is poised to complex with FVa.
These FXa/FVa "prothrombinase" complexes convert II to lIa generating a lIa
burst (6).
The lIa generated during initiation, amplification and propagation is further
utilized in clot stabilization. Fibrinogen is a 340 kDa protein that consists of three
chains (Aa,

B~

and y) forming the homodimer

(AaB~Yh.Thrombin

converts

fibrinogen to fibrin through the cleavage of fibrinopeptides A and B. Fibrin then
non-covalently self associates in the formation of a soft clot (13). The soluble
fibrin clot is then stabilized through y-glutamyl-E-Iysinyl cross-links formed
between the fibrin y - y and y - a chains by lIa-activated FXIII (14). Thrombin
activated FXIII further stabilizes and protects the growing fibrin network from lysis
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by cross-linking it to thrombin-activatable fibrinolysis inhibitor (TAFI) and a2
antiplasmin (a 2AP) (15-17) .
The process of haemostasis has been broken down into three overlapping
stages: Initiation, Amplification, and Propagation . Of the many enzymes and
cofactors involved, the research presented here focuses FXIII. The use of
techniques such as HDX coupled with MALDI-TOF-MS aim to shed light into the
illusive FXIII conformational changes.
Transglutaminase Factor XIII

FXIII-A2 has gained much

Activation Peptide

interest over the last couple
decades due to its presence in the
cytoplasm of several different cell
types: macrophages,
megakaryocytes, and connective
tissue histiocytes to name a few
(19-21). Factor XIII plays an

Figure 3: Labeled FXIII-A (1 FIE) This figure was
made using PyMol(18) .

integral role in the coagulation cascade, and there is much need to investigate
the conditions that affect activation/activity as well as the structural dynamics of
the enzyme during activation. A better understanding of the structural changes
around the active site of FXIII during activation, as well as how it interacts with
the other enzymes and proteins involved in the coagulation cascade, could lead
to more targeted therapeutic agents for treatment of excessive bleeding,
thrombosis, and atherosclerosis.
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The action of Factor XIII was first reported in the early 1920s when Barkan
and Gaspar observed that fibrin clots formed in the presence of Ca 2+ were
insoluble in weak bases (22) . Over 25 years later in a letter to Nature, Lorand
reported that a protein was responsible for the formation of insoluble clots
because the "fibrin stabilizing factor" was thermolabile, nondialyzable and
required Ca 2+ (23). Then after the acknowledgement of fibrin stabilizing factor as
a clotting factor in 1963 by the International Committee on Blood Clotting
Factors, it became factor XIII (24). It soon became obvious that FXIII was
essential for stabilizing the non-covalent soft clots formed in blood coagulation
after thrombin cleaves the A and B fibrinopeptides from fibrinogen.
Factor XIII is a protransglutaminase in plasma with a tetrameric structure
consisting of two A subunits and two B subunits (FXIII-A2B2). The details of
FXIII-B will be further discussed in chapter IV, but briefly, all FXIII-A in plasma is
found bound to FXIII-B as a FXIII-A2B2 heterotetramer with an appearant Kd of
25 nM (25) . In platelets, FXIII-A2 is found without the B2 dimer and is referred to
as cellular FXIII (26) . The -83 kDa factor XII I-A has been successfully
expressed and the recombinant form , rFXII I, has been subsequently crystallized
(27). The crystal structure illustrates the wel l-defined and sequentially folded
domains: the activation peptide (1-37) , the
core (185-515) , ~-barreI1 (516-628), and
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~-sandwich

~- barreI2

(38-184) , the catalytic

(629-730) (Figure 3).
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Figure 4: Factor XIII activation scheme . A) Plasma FXII I activation . Intact FXIII-A2B2, thrombin cleaved
a
FXIII-A', Ca 2+ induced dissociation of FXIII-A2 and FXIII-B2 yeilding active FXIII-A" (FXllla" ) . 8 - D)
Cellular FXIII-A2 activation . 8) Thrombin proteolytic activated FXIII-A2, thrombin cleaved FXIII-A' and fully
a
2
active FXIII-A" (FXllla" ) in the presence of low mM Ca +. C) FXIII-A2 nonproteolytic activation in the
2
ca
presence of high (50 mM) [Ca +] FXIII-A" (FXllla ) D) FXIII-A2. nonproteolytic activation in the presence of
Na
low mM Ca 2+ and high (> 150 mM) NaCI yielding FXIII-Ao (FXllla ) .

When FXIII is activated physiologically (Figure 4) , thrombin (lIa) cleaves
the N-terminal activation peptide (residues 1-37). Following activation peptide
cleavage , both low mM Ca 2+ and the C-terminal portion of the fibrin a-chain
assists in the dissociation of the two B subunits (28-32). Once the FXIII-A2 is free
from FXIII-B2 it is active (FXllla lla ). Factor XIII exists as a dimer and the active
site consists of a catalytic triad (C 314 , H373 and D396 ). The catalytic C314 has an
apparent pKa of 6.0, similar to that of a histid ine imidazole (33) . The hydroxyl
oxygen of Y560 forms a hydrogen bond with C314 (27) . This H-bonding
interaction is indicative of a thiolate - imidazolium pair (34) . The catalytic sulfur
anion is stabilized at physiological pH through the H-bonding with Y560 and ionpair interactions with the H373 imidazolium (27, 34-35) .
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Oimer formation is important for the stability of FXIII-A. The dimer
interface covers 2280 A2 and there is a 10.3 - 14.4 kcal/mol decrease in its free
energy upon dimerization (36). When in the presence of a suitable acyl-donor
glutamine containing substrate, C314 of FXllla forms a thioester bond and
ammonia is released. The acyl-donor substrate is then covalently linked to a
primary amine (lysine) acyl-acceptor forming v-glutamyl-E-Iysine cross-links
between the a- and v-chains of fibrin which stabilizes the growing clot. In
addition to clot stabilization, FXIII also assists in protecting the clot from plasmin
degradation via crosslinks between the Aa-chain of fibrin and a2 antiplasmin( 15,
17,37).

FXIII can also be non-proteolytically activated (Figure 4 C and D) when
the Ca 2+ concentration is greater than 50 mM (FXllla ca ) (38-39). Under these
non-physiological conditions the activation peptide is not cleaved and the
enzyme shows activity. Another nonproteolytic activation mechanism has been
demonstrated that is more physiologically relevant. When the factor XIII-A2
subunits are in the presence of 150mM Na+ with low mM Ca 2+ (FXllla Na ), albeit
slow, transglutaminase activity is observed (40). When haemostasis concludes,
one means that FXIII-A2 can be rendered inactive is through cleavage at the
secondary cleavage site (K513-S514).
Hydorgen Deuterium Exchange (HDX) Coupled with Mass Spectrometry

The major theme underlying this research is establishing the
conformational dynamics of FXIII-A2 in solution. The FXIII-A2 crystal structures
provided to date for zymogen (27), FXlila lia (41), and FXllla ca (42) display no
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significant RMSO between the activated and unactivated forms. The active site
is occluded in all crystal structures so an active conformation has yet to be
observed. In an effort to gain a better understanding of FXIII-A2 during
activation, HOX has been utilized in several studies (43-46). HOX has proved to
be a worthy method of isolating structural changes to defined regions of the
molecule
Proteins in solution are not static and in fact are naturally moving, flexing,
and possibly even opening and closing. These movements termed,
conformational dynamics, are difficult to monitor and impossible to see via
crystallography. One benefit of HOX in the field of protein dynamics is the
needed sample size. A typical HOX sample contains 12 IJI of 30 - 50 IJM protein
whereas NMR would require approximately 350 IJI and preferably> 100 IJM
protein. At pH 7.0 exposed protein backbone amide hydrogens exchange with

0 20 within 1 - 10 seconds (47). Within the interior of the protein, exchange is
limited because there is not only restricted access but also nearly all amide
hydrogens are involved in hydrogen bonds. The H-bonding protects the
hydrogen from exchange (48). When running HOX at physiological pH, basecatalyzed exchange is the dominant mechanism of hydrogen exchange. This
occurs in the presence of a catalyst (hydroxide) and a new hydrogen (water)
(47).
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The rate of hydrogen
exchange in an unfolded protein is
dependent upon several factors.
In Equation 1, U and F represent

Equation 1: Rate Constants for hydrogen-deuterium
exchange where F and U represent folded and unfolded
protein respectively (47).

the unfolded and folded protein respectively; therefore, hydrogen-deuterium
exchange is not only dependent upon (k2) , but also the k1 and k1 (the unfolding
and folding of the protein). The exchange kinetics are broken down into two
pathways, EX1 and EX2 kinetics. When k2» k1 EX1 kinetics ensue. Under
EX1 kinetics, there is an unfolding event and the residues involved are
exchanged prior to refolding. This is very rarely seen naturally, without
denaturants. Therefore, EX2 kinetics typically prevail where the protein is quickly
exchanging between two states and the refolding rate is faster than the exchange
rate (k1 »k2)' Once hydrogen-deuterium exchange occurs, the half-life for
amides increases to over an hour by lowering the pH to between 2 and 3 at 0 °C

(48). This low pH -low temperature quench allows for protein digestion and
mass spectrometric analysis.

11

Pepsin Digest
Low pH
Low Temp

MALO 1-TOF-MS and
Analysis of Oeuterim
Incorperation

119
"-829.0
I JllJl

J.,,,JJ !IJl\1 L , I l l
1263.6

1698.2

II,

•

2132 .82567.4

3002.0

Mass (m/z)

Figure 5: Schematic describing the processes involved in hydrogen-deuterium exchange coupled with
MALDI-TOF-MS. The details are in-text.

The details of the method used for each HDX experiment are explained in
the methods section of each respective chapter, Figure 5 is a pictorial
representation to assist in visualizing the process. The starting material is a
lyophilized protein containing hydrogens (blue circles) at all amide linkages. The
protein is resuspended in 0 20, introducing the protein to a deuterium (red circles)
environment. During the 10 minute room temperature incubation , the hydrogens
are given time to exchange with the deuterons as described by the kinetic regime
presented above. To quench the exchange, samples were placed on ice and
trifluoroacetic acid was added dropping the pH to 2.2 . The protease utilized was
pepsin due to its ability to function at low pH. After 10 min , aliquots of the peptic
digestion were quick-frozen in liquid nitrogen and stored cryogenically until analysis.
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Matrix was added to the sample spotted on MALOI plates for analysis. The
spectra in Figure 5 are a representative FXIII-A2 pepsin digest. The three
spectrum labeled A, Band C represent an undeuterated spectra (A), and two
different states (B) and (C) where (C) displays the highest level of deuterium
incorporation or exposure.
Hydrogen-deuterium exchange coupled with mass spectrometry provides
an extremely powerful tool to analyze the conformational dynamics of proteins in
solution. In the research presented HOX has successfully identified regions of
FXIII that experience protection or exposure due to physiological Ca 2+
concentrations, as well as after non-proteolytic activation. To approach the
question of whether FXIII-A2 adopts an open conformation when activated, FXIIIA2 HOX was compared to transglutaminase 2 (TG2), an enzyme with the same
domain structure as FXIII, in both an open and closed conformation. Lastly, the
interface between FXIII-A2 and FXIII-B2 is not well defined and HOX has
uncovered the regions of FXIII-A that become protected when in the
heterotetramer conformation.
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Research Goals

FXIII-A2 solution conformational dynamics is the basis of all research
presented in this dissertation. The overarching goal is to gain a better
understanding of the solution structure of FXIII-A and understand how it interacts
with substrate. HDX was the primary method for studying FXIII-A conformational
dynamics, but NMR was utilized in analyzing aC (233 - 425) structure in solution
with FXIII-A2 (described in chapter V).
In Chapter II, the FXIII-A2 conformational dynamics journey starts by
investigating the solution structure of FXIII-A2 in the presence of physiological
2
Ca + (1 mM)(44). To determine whether the conformational changes seen in the
presence of Ca 2+ were Ca 2+ specific, Mg2+, 8a 2+ and Cu 2+ were also investigated.
Non-proteolytically Ca 2+ activated FXllla ca was also analyzed by HDX and
compared to FXllla Na . These HDX studies led to many new discoveries
concerning the Ca 2+ specific conformational dynamics of FXIII-A2 both before (1
mM Ca 2+) and after activation.
After Pinkas et al. reported that the transglutaminase TG2 could be
trapped in an open conformation (49), HDX was utilized to determine if FXIII
assumed a similar open conformation. Chapter III describes the conformational
dynamics of TG2 in the activated state and also in the open state after inhibition
with TG-DON. HDX has already been used to analyze FXIII-A2 in the activated
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state (Chapter II) and inhibited with the substrate peptide Kg-Don (43). TG2
conformational dynamics have yet to be investigated by HDX and these analyses
allow for a great comparison for FXIII-A to a known 'open' conformation.
The previous studies focused on the conformational dynamics of FXIII
during the last phases of activation. Chapter IV took a step backward in the
activation process to investigate the interaction between FXIII-A2 and FXIIIB-2.
The FXIII-A2B2 heterotetramer plays a major role physiologically but the interface
between the FXIII-A and FXIII-B subunits is not very well understood. HDX once
again proved to be an invaluable tool in determining the regions of FXIII-A2 that
become protected when bound to FXIII-B2.
When studying protein conformational dynamics, it is beneficial to
establish an expression system for your protein of interest. The development of
an expression system opens the doors to introducing mutations and/or the
incorporation of isotopic labels for NMR analysis. The aC domain of fibrin is
known to interact with FXIII-A2B2 and the aC (242 - 424) region aids in the
dissociation of FXIII-A2B2 (28). Chapter V describes the expression system
established and utilized to express 15N_ aC (:233 - 425). The 15N-labeled aC was
then analyzed via 15N-HSQC to determine if lit adopted any compact structure
when interacting with FXIII-A2.
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CHAPTER II
ROLE OF CALCIUM IN THE CONFORMATIONAL DYNAMICS OF FACTOR XIII
ACTIVATION EXAMINED BY HYDROGEN/DEUTERIUM EXCHANGE
COUPLED WITH MALDI-TOF MS

Introduction
Due to the critical role of FXIII in coagulation, there is a need to better
understand the conditions that influence FXIII activation/activity as well as the
structural dynamics of this enzyme system. Recombinant FXIII A2 has been
successfully crystallized (27), and the resultant structure exhibits well-defined
and sequentially folded domains that include the activation peptide (1-37), the
sandwich (38-184), the catalytic core (185-515),

~-barreI1

(516-628), and

~

~

barrel 2 (629-730) Figure 6.
When FXIII is activated physiologically, thrombin (lIa) cleaves the Nterminal activation peptide (residues 1-37). The presence of low mM Ca 2+
assists in the dissociation of the B subunits from plasma FXIII. In addition, Ca 2+
promotes exposure of the catalytic C314 from both plasma and cellular FXIII
resulting in an active A2 dimer (FXllla*) (26, 30, 32). Like other
transglutaminases (TGases), the active site of FXIII consists of a thiol-containing
16

catalytic triad (C314, H373, and 0396) , but FXIII is unique in the fact that it exists
as a dimer.

Figure 6: The FXII I A2 zymogen 2.1 crystal structure 1F13 (50) . (A) A cartoon model to illustrate the
intimate contact at the dimer interface with the domains being color coded (grey) activation peptide,
(white)I3-Sandwich , (black) catalytic core, (white) l3-barrel 1 and (black) l3-barrel 2. (8) Ribbon view of one
FXIII-A monomer with the domains represented by the same colors as (A) . The regions of interest are
labeled: activation peptide (1-37) , Gin recognition peptide 4 (72-97), Gin recognition peptide 7 (190-230) ,
catalytic triad (314, 373 and 396) , Tyrosine 560, secondary cleavage site (513-514) and the proposed lysine
recognition reg ion (646-658) . These figures were created using VMD (51).

In addition to Iia proteolytic activation, FXIII A2 can be non-proteolytically
activated when the Ca2 + concentration is greater than 50 mM (FXllla or FXllla ca )
O

(38-39) . FXIII A2 has also been observed in an activated state in the presence of
>150 mM NaCI and low mM Ca 2+ (FXllla Na ) (40) . A related form of nonproteolytic
FXIII activation has been documented in platelets (40, 52-53). Thrombinstimulated platelets may exhibit increased Ca

2

+

levels that promote formation of

an active intracellular FXIII species which has not been hydrolyzed at the R37G38 peptide bond. In plasma , these different forms of nonproteolytic activation
are minimized by the presence of the B2 subunits (54) . Regardless of the mode
of activation, FXllla function can be hindered following hydrolysis at the
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secondary cleavage site (K513-S514) by thrombin (55-56). Occupation of a
nearby site with Ca 2+ and other select metals can help protect this secondary
hydrolysis from occurring (27, 57).
Even though the catalytic C314 is only alkylated by iodoacetamide (IAA)
after activation, (33, 58-59) the crystal structures for FXllia lia and FXllla ca lack
any major structural changes when compared to that of zymogen (27, 41-42).
The Maurer lab has used MALDI-TOF mass spectrometry approaches coupled
with hydrogen-deuterium exchange or chemical modification to probe FXIII
conformation changes occurring in solution. During activation, portions of the
FXIII catalytic core and the A2 dimer interface were found to be more accessible
to solvent (45, 60). By contrast, the addition of an inhibitory peptide with a
glutamine isostere caused selected FXIII regions to become more protected from
solvent (43). As expected from the secondary cleavage studies, Ca 2+ binding
hindered solvent exposure in a FXIII segment around 513-514. Inhibition at the
active site could lead to further long-range decreases in HDX in this region.
A recent paper by Kristiansen and Andersen questions our use of borate
buffer supplemented with CaCI 2for mass spectrometry based projects. Our HDX
studies have not, however, been carried out under deactivated concentrations
(0.3 mM CaCI 2) as they presume, but at 1 mM CaCI 2 following either proteolytic
or nonproteolytic activation. According to their paper, FXIII A2 that is activated
nonproteolytically at 50 mM CaCb and then buffer exchanged into 1mM CaCI 2
maintains 90% of its enzyme activity (61). Moreover, many of the
conformational events reported as being important for FXIII activation have been
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confirmed by HDX studies by Andersen and Faber using a buffer system of 200
mM Hepes, 150 mM NaCl, and 50 mM CaCI 2 (46).
The focus of our present HDX work was to further investigate the
conformational changes that occur to FXIII due to monovalent and divalent cation
binding. FXIII A2 was monitored in the presence of Ca 2+, Mg2+, 8a 2+, Cu 2+, Na+,
tetramethylammonium chloride (TMAC+) or ethylenediamine (EDA2+) with
concentrations ranging from physiological Ca 2+ concentration, 1-2 mM, up to 50500 mM. On its own, the low mM Ca 2+ condition is unable to support FXIII
activity. The HDX effects observed in this environment thus provide valuable
information on early conformational changes needed in preparation for activation.
Often these effects further increased as the Ca 2+ concentration was raised to the
levels required for nonproteolytic activation (50-500 mM). Several of the
conformational changes observed with physiological 1 mM Ca 2+ also occurred
with the other divalent metals whereas other effects were distinct for a particular
metal. In the current investigation, a novel method of nonproteolytic FXIII
activation was characterized utilizing high concentrations of organic cations
TMAC+ or EDA2+. Knowledge gained from these different HDX studies will help
identify the elusive structural roles of different divalent and monovalent cations.
A greater understanding of the conformational dynamics of FXIII will aid in the
development of new therapeutic strategies to control excessive bleeding,
thrombosis, and/or atherosclerosis.
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Materials and Methods
Factor XIII Preparation and Synthetic Peptides
Recombinant human cellular factor XIII A2 (FXIII A 2) was generously
provided by Dr. Paul Bishop (ZymoGenetics, Inc., Seattle, WA). After
reconstituting the lyophilized FXIII in 18 MO deionized water, FXIII was buffer
exchanged into 6.67 mM borate at pH 8.3. The concentration of FXIII was
determined on a Cary 100 UV/vis spectrophotometer. The absorbance was
monitored at 280 nm and concentration calculated with the FXIII extinction
coefficient of 1.49 mllmg cm. Aliquots (36 1-11) of 16.7 I-IM FXIII in 6.67 mM borate
were dried in a SpeedVac (Savant) and stored at -70°C until future use.
The

~

casein derived FXIII substrate peptide K9 (Ac-LGPGQSKVIG-OMe)

was synthesized by Peptides International (Louisville, KY). K9 was reconstituted
in 18 MO deionized water and the concentration was confirmed by quantitative
amino acid analysis (AAA Service Laboratory, Inc., Boring, OR). Purity was
assessed by HPLC and mass spectrometry approaches.

Transglutaminase Activity Assay
Factor XIII activity was determined using a modified version of the OadeBehring Berichrom Assay (62-63). Briefly, this assay utilizes a coupled reaction
involving both FXIII and glutamate dehydrogenase (GOH). FXllla reacts with the
acyl-donor K9 releasing NH3 and the transglutaminase reaction concludes when
the primary amine acyl-acceptor, glycine ethyl ester, forms an isopeptide bond
with the K9 peptide. This transglutaminase activity is monitored via the
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conversion of a-ketoglutarate and NH3 into glutamate in the presence of reducing
equivalents of NADH. The oxidation of NADH results in decreased absorbance
at 340 nm.
Dry FXIII aliquots were activated nonproteolytically in a total volume of 12
1-11 dH 20. The final working concentration was 50 I-IM FXIII in 20 mM Borate at

pH 8.3 with 50 mM CaCI 2, 50 mM MgCI2 with 2 mM CaCI 2, 50mM BaCI 2with 2
mM CaCb, 50 mM CuCI 2 with 2 mM CaCb, 500 mM ethylenediamine (EDA2+)
with 2 mM CaCI 2, 500 mM NaCI with 2 mM CaCI 2, and 500 mM
tetramethylammonium chloride (TMAC+) with 2 mM CaCI 2}. FXIII was activated
for 10 min at 37°C before adding 3 1-11 to the assay. For each assay, the volume
of activator reagent (163 I-II) and detector reagent (250 I-II) as well as the
concentration of FXIII (300 nM) and Kg (500 I-IM) were held constant (64). The
assay contents were placed in a Cary 100 UV/vis spectrophotometer for 2 min at
37°C for equilibration before the Kg substrate peptide was added. After
introducing the Kg peptide, the oxidation of NADH was monitored for 25 minutes
at 340 nm. Due to the coupled nature of this FXIII activity assay, there is a brief
delay before consumption of NADH can be detected. The FXIII transglutaminase
activity was later determined by the steepest part of the slope which correlates
with enzyme catalyzed velocity

(~abs/min).

The final divalent and monovalent

cation concentrations in the assays ( 0.3-3 mM) did not interfere with GDH
reactivity. Using the molar absorptivity value for NADH (6220 M- 1cm- 1 at 340nm),
the transglutaminase based velocities were converted into (I-IM/min) and the final
velocity values compared. For the studies involving the novel cations EDA2+,
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Na+, and TMAC+, transglutaminase activity was compared relative to that of
FXlIl Ca with % FXlIl Ca Activity defined as (FXllla activity I FXlll ca ) x 100.
Standard Deviations of the mean for three independent trials were calculated.

HDX Experimentation
There were two different groups of HDX samples, one monitoring the
effects of low mM concentrations of divalent metals and the other examining nonproteolytic activation. Both groups utilized the dry buffer exchanged FXIII
aliquots. To probe the effects of low mM divalent metals, 0.6 IJI of 20 mM metalchloride (CaCb, MgCI 2, BaCI2 or CuCI 2) was added to the dry FXIII aliquot and
evaporated to dryness in the SpeedVac and stored at -70°C. The following HDX
protocol was then adapted from methodology established in the Komives
laboratory (65-66). The dry FXIII aliquot was allowed to reach room temp before
12 IJI of 99.996% D20 (Cambridge Isotope Laboratories) was added yielding a
final working concentration of 50 IJM FXIII and 1mM Ca 2+, Mg 2+, Ba 2+ or Cu 2+ in
20 mM Borate at pH 8.3. The samples were incubated at room temperature for
10 minutes before the HDX was quenched by adding 120 IJI of chilled 0.1% TFA
at pH 2.5. The quenched reaction was then immediately transferred to a tube
containing activated pepsin bound to 6% agarose (Thermo Scientific, Rockford,
IL). Pepsin digestion occurred for 10 min on ice. Following digestion, the
reaction mix was centrifuged for 30 sec to separate the FXIII digest from the
pepsin beads. Three 8.2 IJI aliquots were immediately frozen in liquid N2 and
each reaction condition was performed three times.
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When investigating nonproteolytically activated FXIII, aliquots were
prepared as described previously. Divalent and monovalent cations « 3 1-11) were
added to the dry FXIII aliquot for each of the activation conditions (50 mM Ca 2+,
500 mM ethylenediamine (EDA) with 2 mM Ca 2+, 500 mM Na+ with 2 mM Ca 2+,
and 500 mM tetramethylammonium chloride (TMAC+) with 2 mM Ca 2+) and
evaporated to dryness in a SpeedVac and stored at -70°C. After allowing the
sample to reach room temperature, 12 1-11 99.996% 0 2 0 was added and the HDX
occurred at 3TC for 10 min. The activated FXIII was digested and quenched as
stated above.
HDX Analysis
A FXIII(a) HDX aliquot was thawed at room temperature and immediately
mixed with an equal volume of 10 mg/ml a-cyano-hydroxycinnamic acid matrix
(a-CHCA) (Aldrich) in 1:1:1 ethanol/CH 3CN/0.1%TFA at pH 2.2, and 0.51-11 was
spotted on a chilled MALDI plate. The sample spot was then quickly dried by
placing the MALDI plate into a SpeedVac. The plate was then immediately
inserted into the MALDI-TOF-MS (Voyager DE-Pro, Applied Biosystems). By
limiting time for this procedure to < 5 min, HDX back exchange is kept at a
minimum. Spectra were collected in reflector mode with 256 shots/spectrum. All
peptides in the peptic digest were previously identified by Brian T. Turner, Jr. (45)
and/or confirmed by MS/MS analysis on an Applied Biosystems 4700. The
MS/MS peptide identifications were performed using Applied Biosystems GPS
software which utilized the Mascot database. Peptide identification was
confirmed through observing the same peptide sequence in multiple independent
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digests, with an ion score preferably above 20 (peptic peptides Appendix C).
After digestion by pepsin, the FXIII A2 peptides identified represent 40 %

1

SETSRTAFGG RRAVPPNNSN AAEDDLPTVE LQGVVPRGVN LQEFLNVTSV HLFKERWDTN 60

61

KVDHHTDKYE NNKLIVRRGQ SFYVQIDFSR PYDPRRDLFR VEYVIGRYPQ ENKGTYIPVP 120

121 IVSELQSGKW GAKIVMREDR SVRLSIQSSP KCIVGKFRMY VAVWTPYGVL RTSRNPETDT 180
181 YILFNPWCED DAVYLDNEKE REEYVLNDIG VIFYGEVNDI KTRSWSYGQF EDGILDTCL! 240
241 VMDRAQMDLS GRGNPIKVSR VGSAMVNAKD DEGVLVGSWD NIYAYGVPPS

AWTGSVD~

300

301 EYRSSENPVR YGQCWVFAGV FNTFLRCLGI PARIVTNYFS AHDNDANLQM DIFLEEDGNV 360
361 NSKLTKDSVW NYHCWNEAWM TRPDLPVGFG GWQAVDSTPQ ENSDGMYRCG PASVQAIKHG 420
421 HVCFQFDAPF VFAEVNSDLI YITAKKDGTH VVENVDATHI GKLIVTKQIG GDGMMDITDT 480
481 YKFQEGQEEE RLALETALMY GAKKPLNTEG VMKSRSNVDM DFEVENAVLG KDFKLSITFR 540
541 NNSHNRYTIT AYLSANITFY TGVPKAEFKK ETFDVTLEPL SFKKEAVLIQ AGEYMGQLLE 600
601 QASLHFFVTA RINETRDVLA KQKSTVLTIP EIIIKVRGTQ VVGSDMTVTV QFTNPLKETL 660
661 RNVWVHLDGP GVTRPMKKMF REIRPNSTVQ WEEVCRPWVS GHRKLIASMS SDSLRHVYGE 720
721 LDVQIQRRPS M
Figure 7: FXIII peptides observed by MALDI-MS after 10 minute pepsin digestion are underlined. The
underlined peptides represent 40 % coverage.

coverage (Figure 7). These peptides focus on key FXIII regions found within the
~-sandwich,

the catalytic core, and the

~-barreI1

region. Additional studies with

acid dependent type XIII protease did not significantly improve sequence
coverage. All the MALDI spectra derived from pepsin digests were analyzed
using Data Explorer (Applied Biosystems) and calibrated using two singly
protonated reference peptides; monoisotopic mass 850.4787 Da (residues 535541) and quadraisotopic mass of 1375.7097 Da (residues 220-230).
Deuterium incorporation for each isotopic cluster was quantified as
described by Sabo et al. (67). To determine the change in deuteration for FXIII
under different conditions the percent deuteration for each peptide was
calculated using equation 1:
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"difference = (D - Dp::l1 ) x 100

Dmaxi

;

(1)

where OFXIII is the amount of deuterium incorporated in FXIII zymogen, 0 is the
amount of deuterium incorporation in FXIII under different conditions and Omax is
the theoretical maximum amount of deuterium incorporation for the given peptide
under these conditions. The theoretical maximum depends on the final
percentage of 0 2 0 under quench conditions (4.5 %) and accounts for all
exchangeable backbone amide protons as well as a fraction of N-terminal, Cterminal and side chain exchangeable protons. In accordance with previous
HOX data analysis, percent differences greater than 4.5 % are considered
significant (45, 67-69),3 - 4.5 % is moderate and < 3 % is modest.
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Results
1 mM Divalent Metals and FXIII - HDX-MS
Human plasma contains 1-2 mM calcium, therefore the solvent
accessibility of FXIII zymogen (without metals) was compared to that of FXIII in
the presence of 1 mM Ca 2+, Mg2+, 8a 2+ or Cu 2+. All studies would thus be carried
out in the presence of a physiological cation concentration environment. Prior
knowledge about these divalent cations includes the following derived from
studies carried out at concentrations from 0.1 to 10mM. Mg2+ is smaller in size
than Ca 2+ and does not promote the conformation-based fluorescence changes
that are observed upon Ca 2+ binding to FXIII (70).

Mg2+ also does not support
2·
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Figure 8: The number of deuterons incorporated at 10 min for FXIII under the following conditions
zymogenic (no metal) FXIII (black), 1 mM Ca 2+(up diagonal) , 1 mM Mg2+ (grey), 1 mM Ba 2+ (down
2
diagonal) and 1 mM Cu +(white). The top of the graph illustrates regions of interest in FXIII. Error bars
represent the standard deviation of the mean for 3 independent trials .
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FXllia lia activity but does protect against thrombin-catalyzed proteolysis at the
secondary cleavage site (57, 70). Larger in size than Ca2 +, 8a 2+ exhibits no
protection against secondary cleavage and modest ability to support FXllia

lia

activity (33, 57). Cu 2 + is a transition metal that is closer in size to Ca 2 + and exerts
no protection of the K513-S514 site but can support some FXllia lia activity (33,
57).
For the current conformational studies on FXIII A 2 , Table 1 displays
changes in deuterium incorporation of FXIII zymogen compared to FXIII-(Ca, Mg,

Table 1: Changes in Percent Deuteration: FXIII with 1 mM Metal Relative to FXIII
Zymogen a .
Theo
Residues
1-23
32-40
83-99
88-98
100-111
214-230
220-230
240-247
248-264
248-265
300-314
364-372
407-424
513-522
533-550
632-646

Dmax

23.3
8.9
23.2
10.9
11.8
18.8
12.3
7.5
15.9
18.8
15.8
8.4
18.8
9.7
20.1
14.7

b

1 mM Ca 2+ 1 mM Mg2+
-19.1c
-14.6
-12.7
-6.6
-0.4
-5.6
9.2
7.3
-4.1

8.8
5.6
5.3
2.9
2.1

8.7
3.5
3.6

-9.0
0.5
3.2

-3.4
n/a d
0.7
2.2
3.3
0.3
0.8
-1.0
4.0

1 mM Ba2+
-22.9
-10.9
-6.3
4.6
-5.0
6.2
4.3

1 mM Cu 2+
-20.7
-8.5
-6.5
3.5
-3.6
2.5
3.1

6.3

8.7

3.6
1.4
3.0
-2.9

4.0
2.8

-9.7
-6.0

9.7
-11.3
-6.4

-2.8

-1.9

-7.4
-2.3
-2.8

-11.6
-6.8
-1.1

The % change for a particular peptide was calculated by the following equation: % difference - ((0 OFXIII)/O max) x 100 % , where 0 is the amount of deuterium incorporated in FXIII with metal, OFXIII is the
amount of deuterium incorporated in the zymogenic state (no metal), and Omax is the theoretical maximum
number of exchangeable protons within the indicated peptide. b The maximum number of exchangeable
protons within the indicated peptide, assuming 100 % deuteration. This value accounts for all exchangeable
backbone amide protons and a slight fraction of N-terminal, C-terminal, and side chain exchangeable protons,
which are dependent on the final percentage of 020 in solution under quench conditions (-4.5 %). A fully
deuterated peptide would theoretically have acquired this amount of deuterons. C The values in bold represent
Significant changes in deuteration greater than -4.5 %. d n/a refers to a peptide that was either not observed
in the peptic digest or was not of sufficient intensity to quantify.

a
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Ba and Cu). The total deuterium incorporated for each pepsin-derived peptide is
displayed in Figure 8. Note that the top of the chart highlights the different FXIII
regions where the peptides reside.
Within the

~

sandwich domain, the two main regions of interest are the

activation peptide (1-37) and the putative Gin substrate recognition site (72-97),
also known as peptide 4. After 10 minutes of HDX, the activation peptide
became more protected from solvent relative to its values in the zymogen state of
FXIII. Such protection was observed for all the metals tested and ranged from 6.6 % for FXIII-Mg to -22.9 % for FXIII-Ba. The peptide 4 segment (71), is
represented by the pepsin derived peptides 83-99 and 88-98. For peptide 83-99,
changes in deuteration ranged from -0.4 % for FXIII-Ca to -6.5 % for FXIII-Cu. By
contrast, the region 88-98 became more exposed in the presence of all metals
ranging from 3.5 % for FXIII-Cu to 9.2 % for FXIII-Ca. The different responses
for 83-99 versus 88-98 suggest that the amide protons from residues 83-87
and/or 99 may be responsible for the HDX protection observed for 83-99 in the
presence of divalent metals (Figure 8). Further support for the importance of
residue 99 comes from the observation that the next FXIII segment 100-111
exhibits solvent protection in the presence of all the cations tested.
The catalytic core contains several regions of interest. Peptide 7 (190230), another putative glutamine-substrate region (71), displayed increased
deuterium incorporation for metals when compared to zymogen. FXIII-Ca was
the most exposed for peptides 214-230 and 220-230 followed by FXIII-Ba, FXIIICu, and finally FXIII-Mg. The dimer interface between the two FXIII-A monomers
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(residues 240-265) was another region where increases in deuterium
incorporation for all the metals was observed. Exposure within the dimer
interface (240-247) for FXIII-(Ca, Mg, Ba and Cu) when compared to zymogen
was 5.3, 2.2, 6.3, and 8.7 % respectively. As with the peptide 7 region, FXIII-Mg
exhibited the smallest effect. Interestingly, protection from solvent (-3.4 to -5.0%)
was observed for the residues 100-111. The C-terminal portion of this segment
is located at the dimer interface; however, the more N-terminal portion is found in
a

~-sandwich

region.

The catalytic C314 is found within segment 300-314 and the catalytic
H373 is found one residue outside 364-372. For the 364-372 segment
containing the H373, 1 mM Ca 2+ showed a moderate 3.5 % increase in HDX
exposure whereas the other metals all showed a modest protection. By contrast,
FXIII-Ca displayed considerable exposure (8.7 %) for 300-314 when compared to
FXIII-(Mg and Ba) with 0.8 % and 3.0 % exposure, respectively. FXIII-Cu was
the only condition found to be protected in this region (-7.4 %). FXIII-Cu also
became modestly protected in the region of 407-424 which is N-terminal to the
FXIII Ca 2 + binding site (-2.84 %) and makes contacts across the dimer interface.
FXIII-(Ca, Mg, and Ba), however, displayed increases in deuterium incorporation
for this segment. The 407-424 segment may be influenced by a nearby nonprolyl cis peptide bond that is proposed to playa role in FXIII activation (50).
The

~-barrels

contain the secondary cleavage site (513-514) and the

lysine recognition site (646-658) (72-73). FXIII-(Ca, Mg, Ba and Cu) all displayed
protection within 513-522 when compared to zymogen (-9.0 to -11.6%). The
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nearby FXIII 533-550 is not influenced by 1 mM Ca whereas it is significantly
solvent protected in FXIII-(Mg, Ba, and Cu) at levels of -6.0 to -6.8%. Peptide
632-646 is on the N-terminal end of the proposed lysine recognition site and is
moderately exposed in FXIII-Ca (3.6 %) (73). All other conditions showed little if
any protection in this region of l3-barrel 2.

TGase Activity of Nonproteolytically Activated FXIII
FXIII was
nonproteolytically
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Figure 9: TGase activity of nonproteolytically activated FXIII. Samples were
incubated at 37 °C for 10 minutes then added to the assay components. At 2
minutes (12 min total total) the K9 substrate was added to the assay and the
oxidation of NADH is depicted as a function of time. The experimental
groups are as follows: 50 mM Cu 2+ with 2 mM Ca 2+ (0,0 IJM/min), 50 mM
Ba2+ with 2 mM Ca 2+ (1.98 IJM/min), 50 mM Mg2+ with 2 mM Ca 2+ (9.5
IJM/min) and 50 mM Ca 2+(10,7IJM/min).

Behring
Berichrom assay (64). When incubated in the presence of several different
divalent metals including 50 mM Ca 2+, Mg2+, Ba 2+ or Cu 2+, only Ca 2+ displayed
activity (data not shown). After changing the activation conditions to include 2
mM Ca 2+ with 50 mM Mg2+, Ba 2+ or Cu 2+, minor activity was observed in Mg2+
and Ba 2+ but not Cu 2+ (Figure 9). Factor XIII activity was then monitored using a
series of other nonproteolytic techniques. FXllla ca was compared to FXIII
activated in the presence of 500 mM EDA2+ (FXllla EDA) with 2 mM Ca 2+, 500 mM
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Na+ with 2 mM Ca 2+ (FXllla Na ) and 500 mM TMAC+ with 2 mM Ca 2+ (FXllla™Ac).
Using the slope (IJM NADH consumed / min) as an indicator of activity, EDA2+,
Na+ and TMAC+ displayed an increase in FXIII activity of 291 ± 27.7 %, 156.7 ±
16.3 % and 194.8 ± 5.5 %, respectively when compared to FXllla ca .

Nonproteo/ytical/y activated FXllla - HDX-MS
The conformational dynamics of nonproteolytically activated FXIII were
also probed using HDX-MS. Due to peak suppression in the MALDI, it was not
possible to quantify the deuterium incorporated into FXllla EDA and FXlllaTMAC.
Table 2 thus displays changes in deuterium incorporation of FXIII zymogen
compared to FXIII in 2 mM Ca 2 +, FXllla ca and FXllla Na . The total deuterium
incorporated in each peptide is displayed in Figure 10.
Table 2: Changes in Percent Oeuteration: Nonproteolytically Activated FXIII
a
Relative to FXIII Zymogen .

Theo
Peptide

1-23
32-40
88-98
100-111
220-230
240-247
248-264
248-265
300-314
407-424
513-522
533-550

Dmax

23.3
8.9
10.9
11.8
12.3
7.5
15.9
18.8
15.8
18.8
9.7
20.1

b

2 mM Ca 2+

-1S.3
-12.1
-0.9
-4.5
9.3
7.2
1.4
4.7
7.1
0.2
0.0
2.6

c

50 mM Ca 2+

-8.3
-12.7
-1.9
-S.2
13.2
18.2
n/a d

2.2
7.7
-0.1
1.7
1S.8

50 mM Na+
with 2 mM
Ca 2+
n/a

-12.7
-1.3
-5.9
17.1
19.8
2.5
4.5
11.7
-0.8
1.9
n/a

aThe % change for a particular peptide was calculated by the following equation: % difference

=«0

- OFXIII)lD max) x 100 % , where 0 is the amount of deuterium incorporated in FXIII with metal, OFXIII is
the amount of deuterium incorporated in the zymogenic state (no metal), and Omax is the theoretical
maximum number of exchangeable protons within the indicated peptide. b The maximum number of
exchangeable protons within the indicated peptide, assuming 100 % deuteration. This value
accounts for all exchangeable backbone amide protons and a slight fraction of N-terminal, Cterminal, and side chain exchangeable protons, which are dependent on the final percentage of 020
in solution under quench conditions (-4.5 %). A fully deuterated peptide would theoretically have
acquired this amount of deuterons. C The values in bold represent significant changes in deuteration
greater than -4.5 %. d n/a refers to a peptide that was either not observed in the peptic digest or was
not of sufficient intensity to quantify.
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To ensure activity was achieved during HOX, the same activation
conditions used to confirm nonproteolytic activity were utilized for HOX analysis,
except 0 2 0 was substituted for H2 0. The extent of deuterium incorporation may
vary relative to previous work since this HOX project was conducted at 3rC.
When activated in the presence of 50 mM Ca2+ or in 500 mM Na + with 2 mM
Ca 2+, the 13 sandwich activation peptide of FXllla ca and FXllla Na was more
protected than in FXIII zymogen. This effect was seen in the -12.7 % change
found for residues 32-40 in both FXllla ca and FXllla Na . Residues 100-111 fall
within 4

A of the dimer interface and they too displayed

protection of -6.2 % and -

5.9 % for FXllla ca and FXllla Na , respectively when compared to zymogen.
Peptide 7 within the catalytic core became notably exposed when
nonproteolytically activated leading to a 13.2 % increase in deuterium
incorporation for FXllla ca and a 17.1 % increase for FXllla Na at residues 220-230.
The FXIII dimer interface (240-247) within the catalytic core experienced an 18.2

% (FXllla ca ) and 19.8 % (FXllla Na ) increase in solvent accessibility when
activated.

Increased accessibility was also evident within the catalytic cysteine

containing segment (300-314). This region changed 7.7 % and 11.7 % for
FXllla ca and FXllla Na respectively when compared to zymogen (Table 2). These
various changes in solvent exposure were all greater than what could be
observed under a more physiological 1-2 mM Ca 2+ concentration. Such results
suggest that these two FXIII regions (peptide 7 and dimer interface) become
more solvent accessible as the cation concentration is increased (Figure 5). In a
Na+-containing environment, low mM calcium is required for activation.
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Events occurring within the 13 barrels are also important to consider.
Unlike the studies done in the presence of 1 mM Ca 2 +, no substantial changes in
solvent exposure were observed for

~-barrel

1 residues 513-522 under the

nonproteolytic activation conditions at 37 DC. By contrast, accessibility to solvent
increased steadily from 2 to 50 mM Ca 2 + for the neighboring segment 533-550
(2.6 to 16.8%). Within

~-barrel

2, peptide 632-646 is located N-terminal to the

lysine recognition region (646-658) and exhibited an increased deuterium
incorporation of 6.2 % with FXllla Na .
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Figure 10: The number of deuterons incorporated after 10 min at 37°C for nonproteolytically activated
FXIII. Deuterium exchange was monitored under the following conditions zymogenic (no metal) FXIII
2
ca
(black) , 2 mM Ca + (up diagonal), FXllla 50 mM Ca 2+ (grey) , FXllla Na 500 mM Na+ with 2 mM Ca 2+
(whites) . The top of the graph illustrates regions of interest in FXIII. Error bars represent the standard
deviation of the mean for 3 independent trials .
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Discussion
Calcium plays a vital role in the activation and regulation of cellular (A2)
and plasma (A2B2) FXIII (33, 57-58, 74). HDX provides an effective solutionbased approach for dissecting out how Ca 2+ and other divalent and monovalent
species (Mg 2+, Ba 2+, Cu 2+, Na+, EDA2+, TMAC+) participate in the conformational
dynamics of this transglutaminase.

Impact on Ca 2 + binding site and surrounding regions
The FXIII ion binding helix (485-501) is located within 10 A of ~-barreI1
and also makes contact with the other FXIII-A monomer across the dimer
interface (42, 55, 75). See golden helix in Figure 11. The primary calcium
binding site involves FXIII residues Asn436, Asp438, Ala457, Glu485 and Glu490
(Figure 11 pink sticks) and site-directed mutagenesis studies have demonstrated
that when the glutamate residues are removed, FXIII sensitivity to Ca 2+
decreases (27, 55-56). According to Lewis et al., when Ca 2+ concentrations are
< 2.5 mM, there is one Ca 2+ bound per FXIII-A, but there are up to 8 low affinity

sites when the concentration is raised above that threshold (70). The presence
of strong and weak Ca2+ binding sites has also been confirmed by 43Ca NMR
studies (76). Our studies to determine the conformational dynamics of FXIII A2 in
1 mM metal were performed to mimic physiological Ca 2+ concentrations and to
monitor events where a single Ca 2+ should target the higher affinity metal site on
FXIII. The other divalent metals were examined under these same 1 mM
concentration values.
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Although sequence coverage was not observed for the FXIII calcium
binding site, 40 % of the enzyme including a segment containing (513-514), a
secondary cleavage site that is protected from hydrolysis in the presence of
calcium was observed (57). This site of proteolytic degradation (red sticks) is
located just 12 residues down from the ion binding helix (485-510). See Figure
11. All metals tested at 1 mM concentration (Ca 2+, Mg2+, Ba 2+, and Cu 2+)
demonstrated solvent protection around peptide 513-522. This finding was
surprising considering that Mary et al. reported Ba 2+ and Cu 2+ provided no
protection against 2° cleavage (57).
Unlike the 513-522 region, 1 mM Ca 2+ did not show any deuterium
protection for the nearby 533-550 segment (Figure 11 purple) which is part of an
anti-parallel p-sheet that runs adjacent to 513-522. By contrast, the other divalent
metals Mg2+, Ba 2+ and Cu 2+ all showed substantial protection within 533-550
when compared to FXIII in 1 mM Ca 2+. The HDX results suggest that Ba 2+ and
Cu 2+ exert a greater influence on 533-550 with additional effects on 513-522;
however, these events are not sufficient to protect FXIII from proteolysis. 1 mM
2
Ca + may exert a more direct influence on the secondary cleavage site 513-514.
The ability of 1 mM Mg2+, Ba 2+ and Cu 2+ to influence FXIII dynamics brings
up the question of whether such divalent metals could support nonproteolyticallyderived TGase activity as already observed with Ca 2+. Solutions containing 50
mM Mg2+ or Ba 2+, however, all required the added presence of 2 mM Ca 2+to
produce FXIII activity following 10 minutes of nonproteolytic activation at 3rC.
Furthermore, their levels of enzymatic activity were all less than those for 50 mM
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Ca 2 . By contrast, Factor XIII in 50 mM Cu 2 +, even in the presence of 2 mM Ca 2+,
was not able to yield TGase activity. From these studies, it is evident that a
series of divalent metals can support FXIII activation and TGase activity but low
mM Ca 2 + is still needed to occupy what is likely the high affinity ion binding site
on FXIII.

3-550

Catalytic Triad

2

Figure 11: Illustration of the regions within the catalytic core and the Ca + binding site mentioned in the
conformational dynamics of FXIII A2 (1 F13). FXIII A2 (inset) has each domain labeled: l3-sandwich (blue) ,
catalytic core (red), l3-barrel 1 (green) and l3-barrel 2 (yellow) with the box representing the region of interest.
2
The Ca + binding site (pink) and the ion binding helix (gold) are connected to the secondary cleavage site
513-514 (red sticks) within peptide 513 to 522 (dark blue) through the (green) connector. The influence on
the catalytic triad (light blue sticks) is seen through the (green l3-sheet) connector between peptide 533-550
(purple) and Tyr560 (yellow) . FXIII monomer A is (black) and monomer B is (silver) . Image constructed
utilizing VMD (51) .

As mentioned previously, the FXIII segment 513-522 exhibits a decrease
in deuteration in the presence of 1 mM Ca 2+ and no change is observed for the
segment 533-550. These results led to an interest in monitoring FXIII
conformational dynamics after incubation in an environment of 2-50 mM Ca 2+ at
physiological 3rC . Curiously, the protective effect on 513-522 was lost and
replaced with a steady increase in the exposure of 533-550. In the X-ray
crystals, the FXIII active site is occluded by Y560 (Figure 11 yellow sticks) which
resides only 10 residues from 533-550. Steady increases in Ca 2+ concentration
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might promote movement of Y560 thus assisting C314 exposure to substrate. Xray crystallographers have previously predicted that

~ - barrel

1 must move

somewhat away from the catalytic core during the activation process (42) .
Moreover, Y560 will need to be displaced from its H-bonding interaction with
catalytic C314. Since the active site reg ion becomes more exposed at higher
Ca 2+ levels, it is possible the FXIII 533-550 segment contributes a line of
communication to this process. In further support of this proposal , Andersen and
Faber observed their own increases in HDX based solvent exposure for FXIII
peptides spanning 533-551 , 556-559 , and 560-573 upon formation of FXlli Ca
(46) .

Metal Influence on Dimer Interface
The ion binding helix has direct interactions with the FXIII A2 dimer
interface. According to surface calculations , the dimer interface covers 2280 A2
and there is a 10.3 - 14.4 kcal/mol decrease in FXIII-A free energy upon

Figure 12: An illustration of all peptic peptides wh ich yield sequence coverage along the dimer interface
(1 00-1 11, 240-265 and 407-424) are labeled (red) for FXIII monomer A and (gold) for monomer B. Image
constructed utilizing VMD (51) .
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dimerization (36, 42). Key interactions between the two FXIII-A monomers are
found between K113-D367', K257-E401' and R260-D404'. See Figure 12 for
HDX coverage of the dimer interface. The exposure reported previously (43)
around the dimer interface for peptide 240-247 is also seen in the presence of
just 1 mM Ca 2+. This dimer interface exposure is further supported by increases
in deuterium incorporation now recorded for 248-264 and 248-265. Solvent
exposure around the dimer interface is also observed with 1 mM 8a2+ and Cu 2+
but to a lesser extent by Mg2+. Although 100-111 is also positioned along the
dimer interface, this peptide segment exhibits protection from deuterium
exchange. Only the most C-terminal portion is actually along the dimer interface.
The remaining segment is directed into the p-sandwich region which exhibits
protection. These results indicate that a series of different divalent ions can
disturb interactions between the two FXIII-A monomers. Such events occur even
at Ca 2+ levels insufficient to support FXIII activation.
Further increases in solvent accessibility along the A2 dimer interface (aa
240-264) could be observed when the FXIII was nonproteolytically activated at

3rC with 50 mM Ca 2+ (FXlll ca ) or 500mM Na+/ 2mM Ca 2+ (FXIII Na). Under
different HDX conditions, this same region was seen to increase in accessibility
when activated by lIa as well as when inhibited by IAA and Kg DON (43). The
disruption along the dimer interface due to increasing levels of cations may also
be due to the noncanonical Ca 2+ binding site reported for TG2 (S1 226-233)
which is homologous to 264-271 found on the dimer interface of FXIII (77).
Interestingly, a Yb binding site (Figure 13 green) has been shown by X-ray
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crystallography to be in the vicinity of FXIII residue 271 (42). Vee et al. proposed
that an opening in the FXIII A2 dimer interface may allow for the lysine acylacceptor to access the catalytic core (27).

Catalytic C314 Region and Substrate Recognition
The exposure of the catalytic C314 is imperative for FXIII activity. Of the
metals tested at 1 mM, Ca 2+ promoted the largest increase in solvent
accessibility for the FXIII 300-314 region. See orange peptide in Figure 13. 8a 2+
exerted a mild increase on this region and Mg2+ remained essentially the same
as zymogen. Cu 2+ was unique in that it demonstrated substantial protection of
300-314 when compared to zymogen. These HDX results substantiate the lack
of TGase activity observed in the presence of Cu 2+ and suggest that the
observed solvent protection might thwart substrate interactions around the
catalytic cysteine.

Figure 13: Illustration of the substrate recognition regions and dimer interface mentioned in the
conformational dynamics of FXIII A2 (1 F13) . FXIII A2 (inset) has each domain labeled : l3-sandwich (blue) ,
catalytic core (red) , l3-barrel 1 (green) and l3-barrel 2 (yellow) with the box representing the region of
interest. The sequence coverage around the peptide 7 (cyan) the catalytic triad (red) and their close
proximity to the dimer interface and the Yb binding site 270-272 (green) . Pepsin peptide 300-314 is
(orange) and 407-424 is (magenta). FXIII monomer A is (black) and monomer B is (silver) . Image
constructed utilizing VMD (51).

39

Additional HDX results at physiological temperature revealed that 2 mM
Ca 2+ had nearly the same effect on exposure of the 300-314 region as activating
FXIII with 50 mM Ca 2+ (FXllla ca ). Such results suggest that low mM Ca 2+
contribute to initial exposure of C314. Further conformational changes likely
located within the catalytic core, the dimer interface, and/or

~-barrel

1 must

provide the vital link to achieve full FXIII activation and thus ability to target
actions at C314.
Interestingly, segment 407-424 exhibits increased deuteration at 1mM
Ca 2+ but loses this solvent exposure when the temperature is raised to 3rC and
then 2-50 mM Ca 2 + is employed. The 407-424 segment may be influenced by a
nearby non-prolyl cis peptide bond Q425-F426 that is in proximity to the dimer
interface. Earlier work by our group (60) demonstrated that that FXIII C409 could
be alkylated with NEM when the enzyme was nonproteolytically activated with 50
mM Ca 2+ and then re-equilibrated back to 1 mM. This ability was, however, lost
when the exposed FXIII active site was blocked with an inhibitory Q-containing
peptide (43). Weiss and coworkers proposed that conversion of a FXIII nonprolyl cis peptide bond to the more energetically favored trans could help drive
larger scale conformational changes to fully expose the FXIII active site region
(50). The current increases in Ca 2 + concentration and temperature may have

aided in establishing an environment that helps promote the next alterations in
FXIII conformation. Such an environment may contain a more solvent protected
FXIII 407-424 segment.
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Peptide 4 (72-97) in the

~-sandwich

and peptide 7 (190-230) in the

catalytic core are proposed glutamine substrate recognition regions (71). Peptide
7 is represented by the cyan peptide in Figure 13. FXIII A2 in 1 mM Ca 2+
displayed enhanced solvent accessibility relative to zymogen for both 88-98 and
214-230. This FXIII exposure around the glutamine recognition region also
appears to be Ca 2+specific as it induces the greatest effect compared to the
other metals. By contrast, Cu 2+ exhibited the smallest amount of exposure and
thus appears to be least likely to allow for glutamine recognition. Within peptide
4, there are differences in solvent exposure depending on the metal tested. In
the peptide segment 83-99, the percent incorporation with 1 mM Ca 2+ is
essentially the same as with zymogen whereas Mg 2+, Ba 2+, and Cu 2+ show
protection. Within the peptide segment 88-98, Ca 2+ promoted more exposure
than Mg2+ and Cu 2+. Another region of interest is the Lysine recognition site 646658 in ~-barrel 2 (72). A peptide located N-terminally to this site, 632-646, is only
exposed in the presence of 1 mM Ca 2+, whereas Mg 2+, Ba 2+ and Cu 2+ all display
protection in this region.
The proposed glutamine substrate binding site, peptide 7 (190-230), is
located in close proximity to the Ca 2+ binding site and comes within 3 A of a loop
which connects D438 to E485 and E490 within the Ca 2+ binding pocket. For the
nonproteolytically activated forms FXllla ca and FXllla Na , the residues 220-230
exhibited further increases in deuterium incorporation in comparison to the 1-2
mM Ca 2+ conditions. The peptide 7 substrate recognition sequence is another
example of a FXIII region that undergoes initial conformational changes at
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physiological Ca 2+ levels and then exhibits greater exposure at higher ion
concentrations.

Low mM Metals: Activation Peptide
The activation peptide (1-37) is cleaved by lIa during physiological
activation . Residues 1-23 became protected in the presence of 1 mM Ca 2+ as
well as 1 mM Mg2+, Ba 2+ and Cu 2+. The activation peptide was also protected
after nonproteolytic activation with 50 mM Ca 2+ at 3rC , albeit somewhat less
than 1 mM Ca 2+ at room temperatu re. Both the FXIII 1-23 and 32-40 segments
exhibited protection in the HDX studies.

Figure 14: Illustration of the activation peptide and its intimate contact
the opposing FXIII-A monomer
(1F13) . FXIII A2 (inset) has each domain labeled: l3-sandwich (blue) , catalytic core (red), l3-barrel1 (green)
and l3-barrel 2 (yellow) with the box representing the region of interest. Depiction of the N-terminal activation
peptide of FXIII monomer B (silver surface) labeled according to residue type (green =polar, white =
nonpolar, red = acidic and blue = basic) and Arg11 and Arg12 are shown as (blue) sticks. The AP crosses
the dimer interface and Asp373' from FXIII monomer A is hydrogen bonded to Arg11 in close proximity to
the catalytic triad (yellow) and Tyr560 (orange) . Image constructed utilizing VMD (51).

It was reported recently that the FXIII AP is free in solution after lIa
cleavage and available for binding to monoclonal antibod ies specific to FXIII-AP
(78). Our HDX results suggest that in the presence of Ca 2+ the unhydrolyzed AP
remains tightly associated with FXIII A 2. Figure 14 shows how the activation
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peptide segment straddles across both monomer units and that this segment
contains a combination of polar and nonpolar residues. Moreover, there are
acidic and basic side chains that can participate in stabilizing interactions with the
FXIII surface. Interestingly, R11 (Figure 14 blue sticks) from the activation
peptide segment is hydrogen bonded to 0373' on the opposite unit of the dimer.
This R11 - 0373' interaction is also in close proximity to the FXIII catalytic triad
and the vital Y560. Other hydrogen bonds also seem to anchor the FXIII AP
above the catalytic core.
Earlier studies by Lewis et a/ reported that an additional 8 weak metal
sites could be found on FXIII at higher Ga 2+ concentrations. The AP region
and/or a complementary segment on the p-sandwich domain may accommodate
some of these divalent ions (70).

Further studies will be needed to assess

whether the AP segment may aid in channeling Gin substrates towards the
catalytic core. An alternative possibility is that the binding of large physiological
substrates will later assist in displacing this cleaved portion of FXIII from the
vicinity of the transglutaminase active site.
Further Characterizing Nonproteo/ytic Activation

Polgar et a/. demonstrated that FXIII A2 can be activated albeit slowly by
150 mM NaGI and 2 mM Ga 2+ (40). More efficient activation occurs when NaGI is
raised to the 500 - 1000mM level. Low calcium, however, is still necessary. In
the current work, the organic mono and divalent cations, TMAG+ and EOA2+,
were investigated for the first time. The pH of the TGase activity assay is 7.4 and
2
EOA + pKa1 is 7.56 and pKa2 is 10.71 ensuring a mostly divalent (60 %) EOA2+
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ion. As observed with Na+, TMAC+ and EOA2+ each required some calcium to
elicit FXIII transglutaminase activity. Curiously, TGase activity for the TMAC+,
Na+, and EOA2+ conditions (all containing 2 mM Ca 2+) were greater than that of
50 mM Ca 2+, our standard nonproteolytic activation method. Such results further
emphasize the important role of Ca 2+. Moreover, the novel use of organic
cations EOA2+and TMAC+ suggests that activation is not only driven by metal ion
binding interactions. Unfortunately, ionization issues in the MALOI hindered
ability to carry out HOX projects with FXllla EDA and FXllia TMAC.

Overview of Results:
In the current project, the FXIII A2 was monitored in the presence of Ca 2+,
Mg2+, Ba 2+, Cu 2+, Na+, EOA2+, and TMAC+ with concentrations ranging from 1-2
mM up to 50-500 mM for nonproteolytic activation. Several regions were found
where physiological Ca 2+concentrations initiate the changes needed for activity.
As expected, 1 mM Ca2+ does lead to solvent protection for the FXIII region
containing the 513-514 secondary cleavage site. Surprisingly, Ba 2+ and Cu 2+
could protect FXIII 513-522 and 533-550 from solvent even though these two
divalent cations do not shield against secondary cleavage (57). By contrast,
increasing concentrations of Ca 2+ promoted exposure of 533-550. Such Ca 2+
induced effects may playa role in exposing the FXIII reactive thiol group by
helping to disrupt the H-bond between C314 and Y560. When considering other
cations, Mg2+ and Ba 2+ could both promote non proteolytic activation in the
presence of low mM Ca 2+ whereas Cu 2+ could not. The presence of Cu 2+ seems
to hinder exposure of the active site C314 as well as the Gin substrate
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recognition region. Our HDX studies also revealed that 1 mM Ca 2+ increased
deuterium incorporation at the dimer interface, around the lysine recognition
region (632-646), and at two glutamine substrate recognition regions, peptide 4
(83-99) and peptide 7 (214-230). These trends continued in nonproteolytically
activated FXIII.
There has been much speculation about whether FXIII A2 can adopt an
open conformation similar to that reported by Pinkas et al. for TG2 (49).
Conformational changes to activated FXIII A2 can clearly be observed by mass
spectrometry approaches. The gross increases in solvent accessibility that
would be expected if the p-barrels had pulled fully away from contacting the
catalytic core surface, however, are not observed. The fact that FXIII functions
as a dimer may be a contributing element to the difference in behavior of TG2
and FXIII-A2. The dynamic nature of the FXIII in solution is also important to
consider.
Calcium appears to play an intriguing regulatory role in FXIII (33, 56, 58,
79). Low mM levels already begin to initiate important conformational changes
needed to expose the active site and make the enzyme ready to accommodate
incoming substrates. Often as divalent cation concentration increases, the
effects are also enhanced. Physiologically, FXIII is poised to respond to transient
influxes of Ca 2+ in the presence of a Na+ containing environment (40, 52-53).
Platelet FXIII A2 is quite sensitive to such changes in solution environment and
can be more readily activated nonproteolytically (40, 52-53). The initial
conformation events that have been observed in the current study help set the
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stage for the larger conformational changes that are anticipated in the presence
of a physiological substrate or inhibitor.
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CHAPTER III

COMPARING THE SOLVENT ACCESSIBILIT OF FXIII-A2 TO THE OPEN
AND CLOSED FORM OF TRANSGLUTAMINASE 2.

Introduction
Very few structural changes have been observed in FXIII when comparing
the crystal structures of proteolytically activated and nonproteolytically activated
FXIII to zymogen. TG2 on the other hand was recently crystallized bound to an
inhibitory peptide substrate in an 'open' conformation (49, 51). Comparing these
two enzymes in solution will allow for a much better judgment as to whether the

C

A

Figure 15: Structure of GOP-Bound and Inhibitor-Bound TG2 and FXIII-A2 Oimer. The Nterminal ~-sandwich is in blue, catalytic core in green, and the C-terminal ~-barrel 1 and ~
barrel 2 in yellow and red respectively . A- GOP-bound (closed) TG2 (1KV3) . B- TG2 inhibited
(open) with substrate peptide inhibitor Ac-P(OON)LPF-NH2 (2Q3Z) . C- Factor XIII-A2 dimer
(1 F13) .
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FXIII-A2 dimer also goes through an 'open' conformation like the TG2 monomer
when activated.
Comparing the conformational dynamics of FXIII to that of TG2 offers a
unique opportunity. Although TG2 is physiologically a monomer, it contains the
same 4 domains

(~-sandwich,

catalytic core,

~-barrel

1 and

~-barrel

2) as well as

the same general shape as a FXIII-A monomer. As with FXIII, TG2 is proposed
to go through a major conformational change during activation or substrate
binding, but unlike FXIII, TG2 bound to substrate has now been crystallized in an
open conformation (Figure 15 (49, 80)). TG2 is activated in the presence of
millimolar Ca 2+ but unlike FXIII it is inhibited by guanine nucleotides. The
guanidine nucleotide binding site is located between the catalytic core and

~

barrel 1. When GTP is bound, the active site is blocked by two loops and the
catalytic cysteine (C277) is H-bonded to Y516 a neighboring tyrosine (81). In the
absence of Ca 2+, the GTPase activity of TG2 utilizes several G protein-coupled
receptors to mediate intracellular signaling (21, 25).
The first step in comparing the solvent accessibility of FXIII to that of TG2
is identifying the peptides generated during TG2 pepsin digestion. Pepsin is a
non-specific specific enzyme; therefore, it is difficult to predict cleavage products
but their cleavage pattern is very reproducible when conducted under the same
conditions (pH, Temp., etc.). Once the peptic peptides were identified and
sequence coverage determined, HDX was used to determine the conformational
dynamics of TG2 while unactivated (zymogen), activated in the presence of Ca 2+
and substrate inhibited.
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Although Hausch was the first to inhibit transglutaminase activity by
replacing the substrates reactive glutamine with 6-diazo-5-oxo-L-norlueucine
(DON), Sabo et al.was the first to utilize DON to monitor the conformational
dynamics of a transglutaminase with substrate bound (43, 82). DON is an
electrophilic amino acid which acts as an inhibitor by covalently binding to the
catalytic cysteine via a thioether linkage (Figure 16). The substrate peptide K9
(Ac-LGPG(DON)SLVIG-OMe) was synthesized and utilized to characterize the
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conformational dynamics of FXIII-A2 when activated and bound to inhibitor (43).
HDX was utilized in the current study to monitor TG2 conformational dynamics
during activation as a function of calcium concentration and when bound to TGDON, a gluten peptide (Ac-P(DON)LPF-NH 2) inhibitor substrate. Surprisingly
there was not a gross increase in deuterium incorporation across TG2. Within
the catalytic core, several regions, 451-461 and 369-377, became protected
when activated and inhibited. The regions 259-269 and 475-487 became more
exposed only when TG2 was in an open conformation bound to inhibitor
substrate. There are antibodies already available that are specific for the open
conformation of TG2 and the open conformation is being targeted for
pharmaceutical design. The knowledge gained in understanding the regions of
TG2 that become more accessible to solvent when in the open conformation will
assist in determining whether FXIII-A2 undergoes a similar open conformation
that has been reported for TG2 (49).
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Materials and Methods
Transglutaminase 2 and TG-OON Preparation

Transglutaminase 2 was purchased from Zed ira (Darmstadt, Germany).
Lyophilized recombinant human TG2 (1 mg) was reconstituted in 18 MO
deionized water, then buffer exchanged into 25 mM Tris-base at pH 7.4. The
concentration of TG2 was determined on a Cary 100 UV/vis spectrophotometer.
The absorbance was monitored at 280 nm and concentration calculated with the
TG2 extinction coefficient of 106,020 M- 1cm- 1. The extinction coefficient was
determined using Expasy ProtParam tool (http://web.expasy.org/protparam/).
Aliquots (12 IJI) of 50 IJM TG2 in 25 mM Tris-base were stored at -70°C until
future use.
The gluten derived TG2 inhibitory peptide TG-DON (Ac-P(DON)LPF-NH 2)
was purchased from Zedira (Darmstadt, Germany). The lyophilized powder (10
mg) was solubilized in 1.5 ml DMSO and a sample was sent to AAA Service
Laboratories (Damascus, OR) for analysis. The TG-DON concentration was
determined to be 8.5 mM and stored at 4°C. Purity was assessed by HPLC and
mass spectrometry approaches.
The a2 antiplasmin (a2AP-Q4N) derived substrate peptide
CNQENVSPLTLLKLGN 15 ) was synthesized by SynPep Corp (Dublin, CA). The
a2AP peptide was reconstituted in 18 MO deionized water and the concentration
(6.8 mM) was confirmed by quantitative amino acid analysis (AAA Service
Laboratory, Inc., Boring, OR). Purity was assessed by HPLC and mass
spectrometry approaches.
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TG2 Transglutaminase Activity Assay
TG2 activity was determined using a modified version of the Dade-Behring
Berichrom Assay (62-63). Briefly, this assay utilizes a coupled reaction involving
both TG2 and glutamate dehydrogenase (GDH). Activated TG2 reacts with the
acyl-donor a 2AP-Q4N releasing NH3 and the transglutaminase reaction
concludes when the primary amine acyl-acceptor, glycine ethyl ester, forms an
isopeptide bond with the a2AP-Q4N peptide. This transglutaminase activity is
monitored via the conversion of a-ketoglutarate and NH3 into glutamate in the
presence of reducing equivalents of NADH. The oxidation of NADH results in
decreased absorbance at 340 nm.
TG2 aliquots were diluted to 10

~M

in 25 mM Tris. For each assay, TG2

(200 nM) was in solution with activator reagent (163

~I),

detector reagent (250

~I)

and CaCb (10 mM) (64). For monitoring TG-DON inhibition, TG-DON was also
added (0.01 - 1000 nM). The assay contents were placed in a Cary 100 UV/vis
spectrophotometer and incubated for 8 min at 37°C for before the a2AP-Q4N
substrate peptide was added. Oxidation of NADH was monitored for 30 minutes
at 340 nm and the activity was determined by the steepest part of the slope. The
slope represents the velocity of the reaction as

~abs/min.

TG-DON is solubilized

in DMSO, therefore a control experiment was run to confirm that 2 % DMSO did
not affect activity of TG2 (data not shown). In previous studies, Factor XIII
activity also was not affected with 2 % DMSO (43).

HDX Experimentation
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Hydrogen deuterium exchange was utilized to elucidate regions of TG2
that become more accessible to solvent when activated and inhibited. A 12 IJI
aliquot of 50 IJM TG2 was allowed to come to room temperature. Due to TGDON being solubilized in DMSO, all samples were adjusted to the same
concentration of DMSO. TG2 zymogen was prepared by adding 1.0 IJI dH 20 and
0.3 IJI DMSO to a 12 IJI aliquot of 50 IJM TG2 for an assay concentration of 45 IJM
TG-2 in 2 % DMSO. For Ca 2+ activated TG2, 1.0 IJI 26.6 mM CaCb and 0.3 IJI
DMSO were added to a 12 IJI aliquot of 50 IJM TG2 for an assay concentration of
45 IJM TG2 in 2 mM Ca 2 + and 2% DMSO. Lastly, the activated and inhibited TG2
was prepared by adding 1.0 IJI 26.6 mM CaCb and 0.3 IJI 8.5 mM TG-DON to a
12 IJI aliquot of 50 IJM TG2 for an assay concentration of 45 IJM TG2 in 2 mM
Ca 2 +, 191 IJM TG-DON and 2% DMSO. Each sample was incubated at 37°C for
10 min. then evaporated to dryness in a CentriVap Centrifugal Vacuum
Concentrator (Labconco, Kansas City, MO) and placed at -70°C until use.
The following HDX protocol was adapted from methodology established in
the Komives laboratory (65-66). The dry FXIII aliquot was allowed to reach room
temp before 12 IJI of 99.996% 0 2 0 (Cambridge Isotope Laboratories) was added
yielding a final working concentration of 50 IJM TG2, 2.2 IJM Ca 2+ and 213 IJM
TG-DON. The samples were incubated at room temperature for 10 minutes
before the HDX was quenched by adding 120 IJI of chilled 0.1% TFA at pH 2.5.
The quenched reaction was then immediately transferred to a tube containing
activated pepsin bound to 6% agarose (Thermo Scientific, Rockford, IL). Pepsin
digestion occurred for 10 min on ice. Following digestion, the reaction mix was

53

centrifuged for 30 sec to separate the TG2 digest from the pepsin beads. Three
8.2 IJI aliquots were immediately frozen in liquid N2 and each reaction condition
was performed three times.
In addition to investigating TG2 while inhibited with TG-DON, TG2 was
also activated under different concentrations of Ca 2+ (2, 5, and 10 mM) in the
absence of DMSO, and it was determined that DMSO did not playa role in the
conformational changes reported (data not shown).
HDX Analysis
A FXIII(a) HDX aliquot was thawed at room temperature and immediately
mixed with an equal volume of 10 mg/ml a-cyano-hydroxycinnamic acid matrix
(a-CHCA) (Aldrich) in 1:1:1 ethanol/CH 3 CN/0.1%TFA at pH 2.2, and 0.51J1 was
spotted on a chilled MALDI plate. The sample spot was then quickly dried by
placing the MALDI plate into a SpeedVac. The plate was then immediately
inserted into the MALDI-TOF-MS (Voyager DE-Pro, Applied Biosystems).
Spectra were collected in reflector mode with 256 shots/spectrum. All peptides in
the peptic digest were identified using GPS ExplorerTM after MS/MS analysis on
an Applied Biosystems 4700 in the laboratory of M. Merchant at University of
Louisville. After digestion by pepsin, the TG2 peptides identified represent 37 %
coverage (Figure 17). Peptide identification was confirmed through observing the
same peptide sequence in multiple independent digests, with an ion score
preferably above 20 (peptic peptides Appendix D). These peptides focus on key
TG2 regions found within the

~-sandwich,

the catalytic core, and the

~-barrels.

Additional studies with acid dependent type XIII protease did not significantly
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Figure 17: TG2 peptides observed by MALDI-TOF-MS after 10 minute pepsin digestion . The magenta
area represent peptides observed for TG2 (37 % coverage) .

improve sequence coverage. All the MALDI spectra derived from pepsin digests
were analyzed using Data Explorer version 4 .8(Applied Biosystems) and
calibrated using two singly protonated reference peptides; monoisotopic mass
901.44 Da (residues 369-377) and 2042.18 Da + 11 deuterons at mass 2053.29
Da (residues 668-686).
Deuterium incorporation for each isotopic cluster was quantified as
described by Sabo et al. (67) . To determine the change in deuteration for TG2
under different conditions the percent deuteration for each peptide was
calculated using equation 1 (page 23). In accordance with previous HDX data
analysis, percent differences greater than 4.5 % are considered significant (45,

67-69), 3-4.5 % is moderate and < 3 % is modest.
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Results
TG2 Activity and Inhibition with TG-OON
The kinetics of 02AP as FXIII-A substrate are well established (83). It has
also been demonstrated through a Q2N mutation that FXIII will not utilize the Gin
in position 4 on the 02AP peptide (83). To determine if TG2 also recognizes only
the Gin in position 2, TG2 activity was monitored with 02AP-Q2N as substrate.
Like FXIII, TG2 was not catalytically active in the presence of 02AP-Q2N (data
not shown). The activity of TG2 was confirmed using 02AP-Q4N as substrate.
Following an 8 minute incubation in the presence of 10 mM Ca 2+ at 37°C the
substrate peptide 02AP-Q4N was added to the cuvette. The inhibitory action of
TG-OON on TG2 activity was determined by adding TG-OON to the cuvette
during the 8 minute incubation prior to the addition of substrate. The TG2
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Figure 18: A plot of % inhibition vs the log of TG-DON concentration . Seven separate trials
were performed at varying inhibitor concentrations:TG2 in the absence ofTG-DON ; 15 nM TGDON; 30 nM TG-DON ; 50 nM TG-DON ; 90 nM K9 DON ; 180 nM K9 DON ; and 1000 nM K9
DON . The assay components , TG2, and the indicated amount of TG-DON were incubated for 8
min at 37 · C, at which point the substrate o2AP-Q4N was introduced to the assay. All points on
the curve are marked with red squares and the linear portion used for determining IC50 = 55 nM
is blue diamonds inside red squares.
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concentration during activation was 200 nM and TG-DON was monitored over a
concentration range of 0 - 1000 nM. By plotting the % TGase inhibition versus
log TG-DON concentration, a sigmoidal dose response curve is observed (Figure
18). With a TG2 concentration of 200 nM, the IC 50 was calculated to be 55 nM
TG-DON.
MALDI- TOF- TOF for TG2 Pepsin Peptide Identificaiton

The first step in comparing the solvent accessibility of FXIII to that of TG2
was identifying the peptic peptides for TG2. Pepsin is a non-specific specific
protease; therefore, it is difficult to predict cleavage products but the cleavage
pattern is very reproducible when conducted under the same conditions (pH,
Temperature, etc.). Previously in our lab, the peptic peptides of FXIII were
determined on an Applied Biosystems DE-PRO using Post-Source Decay (PSD)
(45). MALDI-TOF-TOF MS allows for MS/MS capabilities. An Applied
Biosystems 4700 was used for acquiring the MS and MS/MS spectra of TG2
digest products. The mass list was subsequently uploaded into GPS ExplorerTM
software available through Applied Biosystems. Using GPS ExplorerTM to search
the MASCOTTM database 16 peptides were identified representing 37 % of TG2
(Figure 17 in Material and Methods).
HDX Analysis of TG2

Once TG-DON binding and inhibition were confirmed HDX was utilized to
monitor the conformational dynamics of TG2 during activation and in the openinhibited conformation. TG2 has been crystallized in an open conformation
leading to the hypothesis that a gross increase in solvent accessibility would be
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a

Table 3: Changes in Percent Deuteration : Active TG2 (2 mM Ca2+) and Inhibited TG2 (2
mM Ca2+ with TG-DON) relative to TG2 zymogen a.

Residues

Theo. Dmax b

2mM Ca2+

2mM Ca2+ TG-DON

13-26
27-40
32-40
155-161
238-254
260-270
316-330
342-354
370-378
452-462
453-462
476-488
503-509
548-555
561-569
669-687

15.8
15.2
9.4
8.2
18.0
13.0
17.0
12.5
8.0
12.7
11.6
14.9
8.0
9.4
10.2
20.3

-0.3
-0.7
-0.8
-0.4
-0.4
1.1
0.0
3.3
-4.2
-22.6
-23.2
0.2
0.4
2.0
0.5
6.0

-0.4
-0.6
-0.4
-0.7
0.2
4.8
-0.2
3.6
-4.0
-23.4
-23.7
5.3
-0.1
2.3
1.1
8.2

j3-Sandwich

Cat. Core

j3-Barrel 1

@-Barrel 2

aThe % change for a particular peptide was calculated by the following

equation: % difference = «D DFXIII is the
amount of deuterium incorporated in the zymogenic state (no metal), and Dmax is the theoretical
maximum number of exchangeable protons within the indicated peptide. b The maximum number of
exchangeable protons within the indicated peptide, assuming 100 % deuteration. This value accounts for
all exchangeable backbone amide protons and a slight fraction of N-terminal, C-terminal, and side chain
exchangeable protons, which are dependent on the final percentage of D20 in solution under quench
conditions (-4.5 %). A fully deuterated peptide would theoretically have acquired this amount of
deuterons. C The values in bold represent significant changes in deuteration greater than -4.5 %
DFXllI)/D max)

x 100 % , where

0 is the amount of deuterium incorporated in FXIII with metal,

observed by HDX around the catalytic core and

~-barrel

interface. HDX allows

for monitoring TG2 conformational changes in solution, eliminating any possible
artifacts of the crystallization process. There were four peptides monitored within
the N-terminal

~-sandwich

region, none of which displayed any significant

changes in solvent accessibility. The catalytic core was better represented and
several peptides displayed not only increases in solvent accessibility, but also
protection (Table 3 and Figure 19).
There were 8 peptides analyzed representing 41 % of the TG2 catalytic
core (139 - 471). The majority of the catalytic core did not show any large
changes in solvent accessibility. Starting at the N-terminal end of the catalytic
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core, peptide 260 - 270 is the first to show a significant change in deuteration .
When compared to zymogen, TG2 activated with 2 mM Ca 2+ only displayed a 1.1
% increase in solvent accessibility whereas the TG-OON inhibited form increased
4.8 %. Continuing toward the C-terminus, the next notable region was 342 - 354,
where both the Ca 2 + activated and the TG-OON inhibited conformations had a
moderate increase in solvent accessibility, 3.3 and 3.6 % respectively. The next
few regions all experienced protection. The first of which is 370 - 378 which
experienced a -4.2 and -4.0 % protection for Ca 2 + activated and TG-OON
inhibited respectively. There were two peptides spanning from 452 - 462 and
they both became highly protected when both became protected 22 .6 - 23.7 %
9.00
8.00

•

Zymogen

•

2mM Ca"

•

2mM Ca" with TG-DON
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Figure 19: The number of deuterons incorporated at 10 min for TG2 under the following
conditions zymogenic (no metal) TG2 (Blue) , 2 mM Ca 2 + (Red) , 2 mM Ca 2 + with TG-DON
(Green) . Error bars represent the standard deviation of the mean for 3 independent trials .

when activated or inhibited .
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Lastly there are the two

~-barrels (~-barreI1

- 686). The 4 peptides that were analyzed in

472 - 584 and

~-barrel

~-barrel

2 585

1 represented 65 % of the

113 amino acids. Only one peptide, 476 - 488 had a significant change in
solvent accessibility. Like the 260 - 270 region, there was not any notable
change in solvent accessibility when activated with 2 mM Ca 2 +, but there was an
increase was observed when inhibited with TG-DON. When inhibited, there was
a 5.3 % increase in dueteration, whereas Ca 2+ activated TG2 only saw a 0.2%
increase. There was only one peptide (669 - 687) representing 19 % of ~-barrel
2 available for analysis. Peptide 669 - 687 also represented the 19 C-terminal
amino acids of TG2. This region saw increases in solvent availability in both the
Ca 2 + activated and TG-DON inhibited TG2. The Ca 2+ activated increased 6.0 %
and the TG-DON inhibited increased 8.2 % when compared to zymogen.
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Discussion
Lorand and Graham coined transglutaminase 2 "the bete noir" of the
transglutaminase family because it was the first of the TGase family discovered
and its physiological role remains elusive (84). Progress in understanding the
physiological role of TG2 in apoptosis, cell-matrix interactions and human
diseases like Central Nervous System (CNS) neurodegenerative diseases, celiac
disease and cancer has been nicely reviewed (84-86). Understanding the
function and physiological role of TG2 has also been assisted with a greater
understanding of its conformational dynamics (49, 87-89).
Two recent studies have utilized mass spectrometry to monitor the
conformational dynamics of TG2 (87, 90). Greenberg, et al. monitored TG2
activity after lysine modification and determined that acetylation of Lys 444,468
and 663 were essential for inhibition (87). The other study identified a redoxsensitive cysteine triad (Cys 230, 370 and 371) which need to be fully reduced
for TGase activity (90). Pinkas et al. has crystallized TG2 trapped in an open
conformation (49). In the current work, the conformational dynamics of TG2
were monitored in solution, for the first time, through the utilization of HOX
coupled with MALOI-TOF-MS.

TG2HDX
Crystallography has been utilized to investigate the structure of TG2 both
in the inhibited (open) and GOP-bound (closed) conformations (49, 91). It was
apparent that within the

~-sandwich

domain there was very little structural

variability (Figure 20). This lack of conformational dynamics was supported by
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HDX where there were no regions
within the l3-sandwich that
exhibited significant changes in
solvent accessibility.

Catalytic Core
The catalytic core proved to
be more flexible during activation
and inhibition . In addition to the
catalytic triad (C277, H335 and
D358), it also contains the putative

Figure 20:
Overlay comparison of the TG2 13Sandwich domain in the open and closed
conformations . The green represents GDP-bound TG2
in the closed conformation and the grey is the TG-DON
inhibited form of TG2 . The overlay was performed
using the MultiSeq tool in VMD(51) .

Ca 2+ binding sites, the redox-sensitive cysteine triad (C230, 370 and 371) and
two of the three Iysines (448 and 468) that are essential for inhibition after
acetylation (77, 87, 90). The exposure experienced from 260 - 270 falls Nterminally of the catalytic C277. During Ca 2 + activation the 260 - 270 region
experienced a modest (1.1 %) increase in exposure whereas when bound to TGDON, there was a 4.8 % increase in exposure. This region is represented by the
magenta helix (Figure 21) and is separated from C277 by a short l3-strand. The
260 - 270 helix does not change orientation in the GDP-bound versus TG-DON
inhibited crystal structures; therefore, the differences observed in deuterium
incorporation for activated versus TG-DON inhibited TG2 is due to the dislocation
of the l3-barrels. The residues of 260 - 270 are < 10 A from residues 631-635 of
l3-barrel2 in the closed conformation . The movement of the two l3-barrel
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domains during inhibition allows for the 4.8 % increase in deuterium
incorporation.

B

A

452-462

Figure 21: Overlay comparison of TG2 in the open and closed conformations. (A) The green
represents GOP-bound TG2 in the closed conformation and the grey is the TG-OON inhibited form of
TG2 . Regions of interest are labeled according to protection or exposure to solvent after activation and
inhibition. Peptides 452-462 and 370-378 (Blue) experienced solvent protection. Peptide 342-354 (pink)
experienced moderate exposure. Peptides 260-270 and 476-488 (magenta) experienced exposure only
after inhibition. Peptide 669-687 (red) experienced exposure. (B) GOP-bound TG2 in the closed
conformation with the same labeling as (A). (C) Inhibited TG2 in the open conformation with the same
labeling as (A).

In addition to C277, the catalytic triad also consists of H335 and 0358.
Peptide 342 - 354 falls between these two residues and 370 - 378 falls 12
residues C-terminal of 0358. Residues 342 - 354 experienced moderate
exposure when activated and when inhibited (Figure 21 and Figure 22 pink) .
This peptide's conformation did not change in the GOP-bound structure when
compared to the TG-OON inhibited crystal structure. These observations
indicate that 342 - 354 may become more exposed if the solvent accessibility of
GOP-bound TG2 was compared to zymogen . The similar structure of 342 - 354
in GOP-bound and TG-OON inhibited TG2 could be due to the importance of
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maintaining structural integrity between two of the three catalytic residues.
Unlike 342 - 354 which became more exposed and displayed a similar
conformation in the two TG2 crystal structures, 370 - 378 experienced moderate
protection and a conformational
change when inhibited. A
closer look at this region
demonstrated the intimate
contact between 370 - 378 and
C370-C371-.
the catalytic 0358. In Figure
\ 342-354
22, 370 - 378 (ball and stick,
red = closed and blue = open) ,
the region observed in HOX
was viewed with an extension ,

,
Figure 22: Illustration of the intimate connection between
the catalytic triad and peptides 342-354 and 370-378. The
catalytic triad (C277 , H335 and 0358) are green ball and
stick. Peptide 342-354 (pink) is connected to 370-378 (ball
and stick) via a linker containg 0358. Peptide 342-354 and
the linker are labeled according to conformation (red =
closed and bl ue = open) .

355 - 369 (new cartoon), which
contains 0358 . The beta-hairpin motif on the N-terminus of 370 - 378 in the
GOP-bound TG2 lost its character and became random coil in the TG-OON
inhibited TG2 crystal structure. Ouring HOX, the solvent exposure of 370 - 378
decreases 4.2 and 4.0 % for Ca 2+ activated and TG-OON inhibited TG2
respectively when compared to zymogen . In the inhibited form of TG2 the Nterminus of 370 - 378 underwent a conformational change and lay closer to the
surface thus supporting the protection observed by HOX (Figure 22).
There is a disulfide bond reported between C370 and C371 in the open
conformation of TG2 (49, 90) . Stamnaes et al. monitored TG2 under different
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oxidizing (GSH/GSSG) conditions and determined that the vicinal C370 - C371
disulfide was prevalent in the open and oxid ized form (90). The solvent
protection and observed conformational change at the N-terminus of 370 - 378
help to substantiate the evidence of vicinal disulfide formation in the open
conformation .
The Ca 2+ binding site on TG2 has yet to be observed in crystal structures
and has only been identified through modeling and mutations of noncanonical
Ca 2 + binding regions (77, 88) . One such proposed Ca 2 + binding site (S2,
residues 445 - 455) was identified through sequence homology with the FXIII-A
Ca 2+ binding site (77). The HDX of this proposed Ca 2+ binding region is

A

Figure 23; Overlay of TG2 and Factor XIII-A2. (A) The overlay of FXIII-A2 and the closed conformation of
TG2 . One monomer of the FXIII-A2 dimer is shaded while the other is (blue). The GOP-bound (closed) TG2 is
(red) and the catalytic triad is (yellow sticks). (8) The overlay of FXIII-A2 and the open conformation of TG2 .
One monomer of FXIII-A2 is shaded while the other is (blue) . The TG-OON inhibited conformation ofTG2 is
overlaid in (red) and the catalytic triad is (yellow sticks) . The overlay was performed using the MultiSeq tool in
VMO(51) .
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represented by 452 - 462, an alpha-helix that lay in a flexible region between the
catalytic core and j3-barrel 1. The> 20 % protection observed in for 452 - 462
supports the evidence of a noncanonical Ca 2+ binding site in this region.
In addition to the noncanonical Ca 2 + binding site Lai et a/. reported that
K468 is one of three lysine residues that, when acetylated , inhibit TG2 activity
(87). The decrease in TG2 activity after acetylation was attributed to the inability
of this flexible region to change conformation and allow for the open
conformation. The a-helix
character of 452 - 462 in TGDON inhibited TG2 extends Cterminally when compared to
GOP-bound TG2. This
extension of a-helix character
would allow for more intra-helix
H-bonding thus decreasing the
exchangeable protons. The
452 - 462 region was
represented by two peptides
that shared 462 as their Cterminus. Both peptides
experienced the same amount
protection, further supporting
the evidence that the C-

Figure 24: Overlay of FX II I-A2 and the open conformation of
TG2 . One FXIII-A2 monomer (blue) was aligned with TG-OON
(yellow) inhibited TG2 (red) . The other FXIII-A2 monomer
displays a surface projection emphasizing the interference
between the FXIII-A [3-sandwich (surface) and the [3-barreI1 of
TG2 in the open conformation . The overlay was performed
using the MultiSeq tool in VMO(51) .
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terminus is important for the observed protection. This helix lies on the backside
of the 'hinge' during inhibition (opening) of TG2. Due to this placement it is not
surprising that it would become more protected as the TG2 molecule opens.
The conformational dynamics of Factor XIII has been well characterized
by HDX and chemical modification techniques (43-44, 46, 60, 92). TG2 and the
FXIII-A monomer share a high degree of sequence and structural homology
(Figure 23). Due to differences in sequence coverage a direct comparison
between TG2 and FXIII HDX was not possible. One region of FXIII which has
received lots of attention is the exposure of the dimer interface during activation
and inhibition (43-44). The equivalent residues on TG2 were not observed.
There has been debate as to whether FXIII-A2 undergoes a large conformational
change when inhibited like that reported for TG (46, 49). The increase of
exposure around the FXIII-A2 dimer interface would seem to support this
hypothesis; but, if it is assumed that FXIII-A2 opens in a manner similar to TG2,
it would have to overcome substantial steric hinderance between the l3-sandwich
region of monomer 1 and the l3-barrel1 of monomer 2. When the FXIII-A2 dimer
is overlaid on the open conformation of TG2 this blockage between the opposing
monomers of FXIII become evident (Figure 24). Komaromi, et al. have
attempted to model FXIII-A2 undergoing an open conformation and reported that
they had to "eliminate two conformational bumpings by making cuts in the
structure and manually deriving new positions for them" (93). Although the data
provided to date would not suggest a major conformational change in FXIII-A2
during activation, more work needs to be done to place any certainty on this
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hypothesis. Since 2007 when TG2 was captured in the open conformation there
have already been antibodies designed for the detection of the open
conformation (Zedira, Darmstadt, Germany). The possibility of trapping FXIII-A2
in a particular conformation via specific antibodies or pharmaceutals would open
new avenues for dealing with aberrant coagulation.
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CHAPTER IV

UTILIZATION OF HDX TECHNOLOGY TO ELUCIDATE THE FXIII A
RESIDUES CRUCIAL FOR HETEROTETRAMER FORMATION WITH FXIII B.

Introduction

In plasma, factor XIII is a protransglutaminase with a tetrameric structure
consisting of two A subunits and two B subunits (FXIII-A2B2), where the B
subunits act as a carrier for the catalytically active A subunits. All FXIII-A in
plasma is found in the complexed A2B2 form, but the B2 subunits are in excess
and about 50% are in the uncomplexed B2 form (94). To date there is not a
crystal structure available for FXIII-B, but by electron microscopy they appear as
thin flexible and kinked fibers (95). Factor XIII-B is a glycoprotein which contains
8.5% carbohydrate and has a molecular mass of -80 kDa. Structurally, the B
subunit contains 10 "sushi-domain" repeats (Figure 25), each of which consist of
60 amino acids and 2 disulfide bridges (96-97).
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Figure 25: Primary sequence of FXIII B2 illustrating the 10 sushi-domain repeats each containing 60
AA and 2 disulfide bonds. This research was originally published in The Journal of Biological Chemistry.
Ichinose, A., Bottenus, R.E., Davie, E.W. Structure of Transglutaminases. Journal of Biological
Chemistry. 1990; 265:23 13411 - 13414. © the American Society for Biochemistry and Molecular
Biology (96).

Factor XI II-A exists as the -320 kDa A2B2 heterotetramer with a
concentration of 14-28 jJg/ml in plasma. The apparent binding constant for the
association of A2 and B2 subunits was determined to be 4x1 07 M- 1 (Kd

=0.025

jJM)(25). Souri recently utilized several truncated forms of FXIII-B which
contained different regions of the molecule (eg. sushi domains 1-9, 1-5, 1-4,510, etc.) to identify the sushi domains responsible for dimer (B 2) formation and
heterotetramer (A2B2) formation. The fourth and ninth domains are crucial for
dimer formation and the first sushi domain on the N-terminus is needed for
heterotetramer formation (Figure 23) (98). The exact residues on FXIII-B that are
important to the B2-dimer and A 2B2-tetramer formation have not been
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Figure 26: Cartoon model of FXIII 8 homodimer illustrating sushi-domains 4 and 9 (yellow) which
are crucial for FXIII 82 dimer formation and domain 1 (red) which is utilized in heterotetramer
formation with FXIII A2. Figure used from (98) .

determined . When complexed with FXIII-B , FXIII-A is stabilized in plasma
increasing its half-life. The concentration of FXIII-A decreased 40% after 2 hr
incubation at 37 °G. Further evidence of the stabilization of FXIII-A is the
resistance to proteolytic attack by trypsin and thrombin observed when FXIII-A is
bound to FXIII-B (99). When bound , the protective effects of the B-subunit are
well documented , but the FXIII-A2 residues requ ired for tetramer formation have
yet to be elucidated. It is hypothesized that the beta-barrels playa major role in
the tetramer formation because when truncated the tetramer is not observed by
co-immunoprecipitation with an anti-XIII-B antibody (99).
In the current study hydrogen-deuterium exchange coupled with MALDITOF-MS was utilized to unveil the residues on FXIII-A that become less
accessible to solvent when it associates with the B2 subunit forming the A2B2
heterotetramer. Monitoring FXIII-A solvent protection by HDX aided in painting a
more complete picture of how FXIII-A and FXIII-B interact in solution . These
experiments demonstrated that although FXIII-B2 incurs FXIII-A2 proteolytic
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resistance 14 % sequence coverage was still observed. Even with decreased
sequence coverage it was demonstrated that much of the FXIII-A molecule
becomes protected in the presence of FXIII-8, but significant protection is
observed around the dimer interface and both of the beta-barrels. This evidence
supports earlier reports of

~-barrel

involvement in heterotetramer formation (98-

99).
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Materials and Methods
Factor XIII A2 and Factor XIII 8 2 Preparation
Recombinant human cellular FXIII A2 was generously provided by Dr. Paul
Bishop (ZymoGenetics, Inc., Seattle, WA). After reconstituting the lyophilized
FXIII in 18 MO deionized water, FXIII was buffer exchanged into 25 mM Trisbase at pH 7.4. The concentration of FXIII was determined on a Cary 100 UV/vis
spectrophotometer. The absorbance was monitored at 280 nm and
concentration calculated with the FXIII extinction coefficient of 1.49 ml/mg cm.
Aliquots (12 IJI) of 34 IJM FXIII in 25 mM Tris-base were stored at -70°C until
future use.
A 200 IJg ampoule of recombinant human FXIII B2 (Zedira, Darmstadt,
Germany), lyophilized in the presence of 25 mM Tris, was resuspended with 18
MO deionized water to a concentration of 24 IJM. Aliquots of 10 IJI were prepared
and stored at -20°C until use.

HDX Experimentation
Hydrogen deuterium exchange was utilized to elucidate points of contact
between the FXIII A2 and FXIII B2. An aliquot of 24 IJM FXIII B2 and 34IJM
FXIIIA2 were allowed to come to room temperature. For analysis of FXIII A2 in
solution, 6 IJI FXIII was added to 10 IJI 25 mM Tris for a final concentration of 13
IJM FXIII-A. To allow for FXIII A2 and FXIII B2 binding before HDX, 6 IJI 34 IJM
FXIII A2 was added to 10 IJI 24IJM FXIII B2 yielding 13 IJM FXIII A and 15 IJM
FXIII B in solution. All assays were then allowed to incubate for 20 minutes on
ice. Following incubation, the assay tubes were then evaporated to dryness in
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the SpeedVac and then HOX was performed on the dry samples. The following
HOX protocol was then adapted from methodology established in the Komives
laboratory (65-66). The dry FXIII aliquot was allowed to reach room temp before
12 JJI of 99.996% 020 (Cambridge Isotope Laboratories) was added yielding a
final working concentration of 17 JJM FXIII A and 20 JJM FXIII B. The samples
were incubated at room temperature for 10 minutes before the HOX was
quenched by adding 120 JJI of chilled 0.1% TFA at pH 2.5. The quenched
reaction was then immediately transferred to a tube containing activated pepsin
bound to 6% agarose (Thermo Scientific, Rockford, IL). Pepsin digestion
occurred for 10 min on ice. Following digestion, the reaction mix was centrifuged
for 30 sec to separate the FXIII digest from the pepsin beads. Three 8.2 JJI
aliquots were immediately frozen in liquid N2 and each reaction condition was
performed three times.

HDX Analysis
A FXIII(a) HOX aliquot was thawed at room temperature and immediately
mixed with an equal volume of 10 mg/ml a-cyano-hydroxycinnamic acid matrix
(a-CHCA) (Aldrich) in 1:1:1 ethanoIlCH 3 CN/0.1%TFA at pH 2.2, and 0.5 JJI was
spotted on a chilled MALOI plate. The sample spot was then quickly dried by
placing the MALOI plate into a SpeedVac. The plate was then immediately
inserted into the MALOI-TOF-MS (Voyager DE-Pro, Applied Biosystems).
Spectra were collected in reflector mode with 256 shots/spectrum. All peptides in
the peptic digest were previously identified by Brian T. Turner, Jr. (45) and/or
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confirmed by MS/MS analysis on an Applied Biosystems 4700. Peptide
identification was confirmed through observing the same peptide sequence in
multiple independent digests, with an ion score preferably above 20 (peptic
peptides Appendix C). After digestion by pepsin, the FXIII A2 peptides identified
represent 40 % coverage. These peptides focus on key FXIII regions found
within the

~-sandwich,

the catalytic core, and the

~-barreI1

region. Additional

studies with acid dependent type XIII protease did not significantly improve
sequence coverage. All the MALDI spectra derived from pepsin digests were
analyzed using Data Explorer (Applied Biosystems) and calibrated using two
singly protonated reference peptides; monoisotopic mass 850.4787 Da (residues
535-541) and quadraisotopic mass of 1375.7097 Da (residues 220-230).
Deuterium incorporation for each isotopic cluster was quantified as
described by Sabo et a/. (67). To determine the change in deuteration for FXIII
under different conditions the percent deuteration for each peptide was
calculated using equation 1 (page 23). In accordance with previous HDX data
analysis, percent differences greater than 4.5 % are considered significant (45,
67-69), 3-4.5 % is moderate and < 3 % is modest.

Native Gel
To mimic the HDX conditions, prior to running on the gel, 3 j..Il 34 j..IM FXIIIA was added to 5 j..Il 24 j..IM FXIII-B. A 13 j..IM FXIII-A and 15 j..IM FXIII-B aliquot
was also prepared and all samples incubated for 20 minutes on ice. Each
sample was then added to 16 j..Il sample buffer (63 mM Tris pH6.8, 10 % glycerol
and 0.05 % bromophenol blue). The samples were electrophoresed using a 4.0
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% polyacrylamide stacking gel (125 mM Tris-base, pH = 6.8) on a 7.5 %

polyacrylamide resolving gel (375 mM Tris-base, pH=8.8) and a running buffer of
5 mM Tris Base and 38.4 mM glycine pH = 8.3. The gels subsequently were
stained with a 0.1 % Coomassie blue solution containing 40 % Methanol and 10
% Acetic acid. A Gel Doc™ XR+ System (Bio-Rad, Hercules, CA) was then

utilized for gel imaging.
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Results
FXIII-B induced proteolytic resistance
All HDX that have been run in our lab to th is point have included proteins
with a molecular weight of no more than -160 kDa (FXIII-A = -80 kDa) . The
FXIII-A2B2 heterotetramer has a molecular weight of -320 kDa (4 x -80 kDa).
This increase in total protein mass along with the known proteolytic resistance of
FXIII-A in the presence of FXIII-B (98-99) led to an exploratory experiment to
determine the feasibility of performing HDX on this system. Following a 10
minute pepsin digest mimicking HDX conditions. peptides produced were
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Figure 27: Representative spectra for FXII I-A2 (A) , FXIII-B2 (B) and FXIII-A2B2 (C) following pepsin
digestion.

77

monitored for FXIII-A, FXIII-B and FXIII-A2B2 on the MALDI-TOF-MS (Figure
27A-C). At 13 IJM, FXIII-A produced pepsin digest with many clear and
identifiable peaks (Figure 27A). FXIII-B contains 2 disulfide bonds per sushi
domain which infers an innate proteolytic resistance. Due to the proteolytic
resistance, only two major peaks (m/z

= 1350.65 and 2039.95) are found in the

FXIII-B pepsin digest (Figure 27B). FXIII-B did elicit proteolytic protection upon
FXIII-A when in the heterotetramer form as seen in Figure 27C . The intensity of
the most abundant ion (m/z = 1216.70) in Figure 27A is 5 fold higher than that for
the spectra representing 13 IJM FXIII-A in the presence of 15 IJM FXIII-B.
Suppression within the FXII I-A2B2 pepsin digest resulted in a decrease in
sequence coverage for the HDX. After digestion by pepsin, the FXIII-A2 peptides
identified represent 40 % coverage. These peptides focus on key FXII I regions
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there is a large
decrease in sequence

coverage due to lower sensitivity as well as peak interference (overlap of
unidentified peptides) . Following pepsin digestion , FXIII-A2 sequence coverage
reduces to 14 % when bound to FXIII-B2 (Figure 25).

Native Gel - Heterotetramer confirmation
FXIII-A2 has a high affinity for FXIII-B2 (Kd = 25 nM) and is found almost
exclusively as a FXIII-A2B2 heterotetramer in plasma . To confirm FXII I-A2B2
formation for HDX analysis native (no SDS) PAGE was utilized . By mirroring the
solution conditions for HDX, native PAGE identified FXIII-A2 and FXIII-B2 dimers
as well as FXIII-A2B2 heterotetramer formation in solution (Figure 26) . FXIII-A2
migrated the furthest and FXIII-B2 having a similar molecular weight migrated in
almost as far as FXIII-A2. The FXIII-A2B2 complex was confirmed in the higher
molecular weight (slower migrating band) .
After confirming FXIII- A2B2
FXIII-A,

FXIII-B,

FXIII-A,B,

formation , HDX analysis was
performed to monitor the regions of
FXII I-A2 which become more protected
97.4 kDa

97.4kDa

in the presence of FXIII-B2. Due to the
interactions between FXIII-A2 and

Figure 29: Native PAGE illustrating the formation
of FXIII-A2B2. Molecular weight standards are
marked (97.4 kDa) .

FXIII-B2 during heterotetramer
formation , there was a substantial

decrease in sequence coverage. Even with this decrease in coverage, regions of
FXIII-A2 important for heterotetrmer formation were monitored, for the first time,
using HDX coupled with MALDI-TOF MS.
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FXII/-A2B2 HDX Analysis

To date FXIII-A2B2 has yet to be crystallized; therefore, HDX was utilized
in an effort to ascertain the regions of FXIII-A2 that are involved in heterotetramer
formation with FXIII-B2. Since Ca 2+ is a FXIII-A2 cofactor that aids in FXIIIA2B2
separation and FXIII-A2 activation, all studies were run in the absence of divalent
metal cations(39, 58). For the current conformational studies on FXIII A2B2 Table
4 displays changes in deuterium incorporation of FXIII-A2 zymogen compared to
FXIII-A2B2. The total deuterium incorporated for each pepsin-derived peptide is
displayed in Figure 30.
The

~-sandwich

region of FXIII-A2 contains the activation peptide as well

as peptide 4, a Gin
Table 4: Changes in Percent Oeuteration: FXIII-A2B2 relative to
FXIII-A2 zymogen a

substrate recognition
region. Due to the
decrease in FXIII-A2
sequence coverage, there
were not any quantifiable
peptic peptides within the

~-

sandwich region. The
catalytic core contains
several regions of interest.
Another important putative
Gin substrate recognition,
peptide 7 (190-230), is

Residues
137-144
145-159
220-230
240-247
298-305
325-338
328-338
535-541
607-619
632-646

Theo.

Dmax

7.90
15.58
12.31
7.50
7.50
14.40
9.5
6.5
12.80
14.70

6

FXIII-A2B2
-0.8
-1.6

_5.8 d
-16.7
-6.4
0.9
-2.4
-1.2

-14.5
-10.6

a The % change for a particular peptide was calculated by the
following equation: % difference = ((0 - OFxlII)/O max) x 100 % ,
where 0 is the amount of deuterium incorporated in FXIII with
metal, OFXIII is the amount of deuterium incorporated in the
zymogenic state (no metal), and Omax is the theoretical
maximum number of exchangeable protons within the indicated
peptide. b The maximum number of exchangeable protons within
the indicated peptide, assuming 100 % deuteration. This value
accounts for all exchangeable backbone amide protons and a
slight fraction of N-terminal, C-terminal, and side chain
exchangeable protons, which are dependent on the final
percentage of 020 in solution under quench conditions (-4.5 %).
A fully deuterated peptide would theoretically have acquired this
amount of deuterons. C The values in bold represent significant
changes in deuteration greater than -4.5 %
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.

found in the catalytic core(71) . In the peptide 7 region , 220-230 , FXIII-A
experienced significant 5.8 % protection from solvent when bound to FXIII-B.
One of the regions which displayed the most protection when bound to FXIII-B
was the dimer interface. FXIII-A (240-247), underwent a 16.7 % decrease in
solvent accessibility. There were two other regions of the catalytic core
represented (298-305) which showed a 6.4 % decrease in solvent accessibility
and (325-338) which did not change significantly. FXIII-A peptide 325-338 was
the only peptide quantified that displayed an increase (0.9 %) in HDX exposure.
Peptide 328-338 found within 325-338 experienced 2.3 % protection, thus
residues 325,326 and/or 327 must be exposed to explain the 0.9 % exposure of
325-338.

The p-barrels have always been poorly represented during HDX analysis
(43-44, 60) , but they appear to be quite important for FXIII-A2B2 heterotetramer
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formation. Protection within the FXIII-A2 J3-barrel 1 is evident in the 14.5 %
protection at peptide 607-619. This large increase in protection also carries over
into J3-barrel 2 where peptide 632-646, found on the N-terminal end of a
proposed Lys recognition region (646-658) (73), is protected 10.6 % when bound
to FXIII-B2.
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Discussion
Factor XIII has been studied extensively over the past 30+ years and the
knowledge gained is extensive. Ironically very little has been done to determine
how FXIII-A and FXIII-B interact. The recent work of Souri et a/. has shed new
light on the sushi domains that are essential for FXIII-B2 dimer formation as well
as FXIII-A2B2 heterotetramer formation (98). The FXIII-A regions necessary for
heterotetramer formation have also been investigated and it was determined that
the j3-barrels play an integral role (99). These studies have aided in generating a
better understanding of FXIII- A2B2 formation but there still needs to be more
work done to identify the binding epitopes involved on both FXIII-A and FXIII-B.
The preliminary experiments to determine feasibility yielded evidence that
FXIII-B is inherently resistant to pepsin proteolysis. After 10 min digestion on ice,
FXIII-B only produced two quantifiable peptides (m/z

=1350.65 and 2039.95).

This was promising considering that they did not overlap with any of our known
peptic peptides produced in FXIII-A. Although the digest containing only FXIII-B
did not produce any peptides that overlapped with FXIII-A digests, there were
some peaks lost in the FXIII- A2B2 digest due to suppression and/or overlap of
unidentified peptides. The protective effect of FXIII-B on the proteolytic action of
pepsin on FXIII-A was observed in all FXIII-A2B2 digests. FXIII-B has been shown
to stabilize FXIII-A in vitro (98-99). FXIII-B protected wild type and, to a lesser
extent, Y283C FXIII-A from trypsin digestion, but this protection was not seen in
a 1464stop mutant which does not contain the j3-barrels (99). A decrease in
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FXIII-A proteolytic degradation due to heterotetramer formation was not only
observed with trypsin, but also with the more unspecific proteinase K (98). The
intensity of FXIII- A2B2 pepsin digests decreases nearly 5 fold in comparison to
FXIII-A2. This signal suppression can be attributed in part to the proteolytic
resistance of FXIII- A2 when associated with FXII I-B2. The protective effect of
FXIII-B induced a decrease in digestion efficiency leading to a decrease in FXIIIA sequence coverage from 40 % to 14 % (Figure 31).
Once it was determined that HDX was possible with the FXIII- A2B2
complex, a native gel was
utilized to confirm
heterotetramer formation .
FXIII-B2 was the smallest of
the components and thus
migrated the furthest. FXIIIA2 produced a nice band
just above that of FXIII-B2
and heterotetramer
formation is confirmed in
the slower migrating FXIIIA2B2 band (Figure 26). A

Figure 31: Illustration of FXIII-A2B2 HDX sequence coverage .
FXIII-A2 (1 F13)is represented by the ribbons. The cartoon peptides
represent 14 % of the molecule. Protection is noted in (blue) ,
significant protection (purple) and exposure (red) . Image was
constructed utilizing VM D (51)

1:1 ratio of FXIII-A2 to FXIII-B2 has been confirmed in previous studies (9899) .Therefore, a faint FXIII-B2 band is observed in the FXIII-A2B2 lane due to a
small excess of FXIII-B2 (15 !-1M) versus FXII I-A2 (13 !-1M).
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The utilization of

Undeuterated FXIII-A,

HDX to monitor the
conformational dynamics of
FXIII-A,

FXIII-A2 when associated
with FXIII-B2 allows for
identifying regions that

FXIII-A,B,

become protected due to
the heterotetramer

1020.0

1012.1

1021.'

M... (mlz)

formation. It has been
reported that the

~-barrels

playa crucial role in FXIII-

Figure 32: Representative HDX Spectra. The three
representative FXII I-A2 spectra illustrate the isotopic clusters of
peptide 240-247 after 10 min. HDX. The FXIII state is listed in
the fig ure . This peak cluster represents a peptide found on the
FXIII-A2 dimer interface. Protection due to heterotetramer
formation was observed for FXIII-A2B2.

A2B2 formation (99), but it is unknown as to how the rest of the FXIII-A2 molecule
is affected. The sequence coverage of FXIII-A2 can be seen in Figure 31.
Nearly the whole molecule becomes protected when interacting with FXIII-B2.
Within the catalytic core there were three peptides which underwent
significant (>4.5 %) protection. The first regions of importance was the putative
Gin binding site, peptide 7 (190-230) , represented by peptide 220-230 . This
region has been shown to display exposure when activated proteolytically and
non-proteolytically, in the presence of physiological concentrations of Ca 2+ , and
when inhibited (43-44) . It is thought that FXIII-A2B2 is associated with fibrinogen
in plasma . By limiting substrate recog nition at peptide 7, FXIII-B could be
protecting against FXIII-A2 utilizing the fibrinogen as substrate. One peptide falls
along the dimer interface (240-247) and it becomes substantially protected in the
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heterotetramer form as seen by the isotopic cluster shift to a lighter mass (Figure
32). The dimer interface becomes more exposed as FXIII-A2 becomes activated
so therefore, by remaining protected, FXIII-B2 is limiting the ability of FXIII to
aberrantly become activated in plasma. The catalytic cysteine was not
represented, but peptide 298-305 resides 9 residues N-terminally were protected
6.4 % yet again illustrating the protective nature of FXIII-B2 on FXIII-A2.
Prior to the elucidation of the FXIII-A2 crystal structure, Lai et al. utilized
several different C-terminally truncated FXIII-A mutants to define the minimum
structure required for transglutaminase activity (56). When truncated at K513
and A502, FXIII-A affinity for small Gin containing substrates only decreases 2
fold, but the turnover rate experiences a 4 fold decrease. This decrease in
turnover when the l3-barrels are truncated and complete abolishment of activity
when truncated at the Ca 2+ binding site demonstrates not only the importance the
l3-barrels play in primary amine recognition/turnover, but also the necessity of an
intact Ca 2+ binding site within the catalytic core (56). Souri et a/. has nicely
demonstrated the importance of the l3-barrels in heterotetramer formation (9899). FXIII-A 1464stop as well as two mutants that excluded either l3-barrel 1 or

13-

barrel 2 were all unable to form FXIII-A2B2 heterotetramers. In the present study
607-619 in l3-barrel1 and 632-646 in l3-barrel2 experienced 14.5 and 10.6 %
protection from solvent when bound to FXIII-B. These results further
substantiate the hypothesis that the l3-barrels are essential for heterotetramer
formation and give specific residues involved in the FXIII-A2 - FXIII-B2
interaction.
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It is known that in plasma FXI II-A2B2 is largely associated with fibrinogen
(100). The binding site of fibrinogen on FXIII-A and/or FXIII-B has yet to be
identified . Lai et al. demonstrated that even when truncated at Y481, FXIII-A still
binds to fibrinogen even though it has lost> 99 % of FXllla activity (56). It was
proposed that the FXIII-A fibrinogen binding site was independent of the
substrate recognition site (71). The protection seen in the l3-barrels would allow
for FXIII-A2 - FXIII-B2 interactions while still bound to fibrinogen.
Although FXIII-B has not been crystallized, 132-glycoprotein I (132-GPI)
contains similar short
consensus repeats also

38ft.

referred to as GP-Is or
sushi domains.
Topological comparisons
confirmed structural
similarity between the 4
sushi domains of 132-GPI
and the sushi domains in
3 other proteins (r.m.s.d
< 2.5 A) (101). Using

the sushi domains of 132-

Figure 33: 132-glycoprotein I - Representative sushi domain . The two
representative sushi domains are illustrated as (cyan) cartoon ribbons
with the four cysteines involved in disulfide bond denoted as (red)
sticks. Each sushi domain is - 38 x 17 x 20 A so therefore, the 10
FXIII-8 sushi domains would span -380 A(101) .

GPI as a model, it was
determined that a typical sushi domain is 38

A x 20 A x

therefore, an elongated FXIII-B would be -380
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17 A (Figu re 30),

A in length (101).

The FXIII-A2

dimer has a length of -102

A and each

~-barrel is approximately the same size

as a sushi domain (41-42). If FXIII-B2 took the orientation proposed by Souri et
al. (Figure 30) where the first sushi domain of each FXIII-B was interacting with
the

~-barrels

and domains 4 and 9 were involved in FXIII-B2 dimer interactions,

FXIII-B2 would stretch> 380

A.

Since the FXIII-A2 dimer is only 102 A, the FXIII-

B2 dimer would create a D-shaped loop tethered by the first sushi domain to
opposing FXIII-A2

~-barrels.

Judging by the HDX results, the FXIII-B loop elicits

protection across FXIII-A2, but solvent protection is primarily observed at the

~

barrels (the putative FXIII-B2 binding site) and the dimer interface.
HDX has allowed for the first glimpse of the regions of FXIII-A2 that play
an integral role in FXIII-A2B2 heterotetramer formation. It has long been known
that when bound to FXIII-B2, FXIII-A2 is protected from proteolytic degradation.
The near global HDX protection observed in FXIII-A2 in the FXIII-A2B2
heterotetramer, brings forth new evidence of the protection bestowed upon FXIIIA 2. The data presented here further emphasizes the importance of the FXIII-A2
~-barrels

in the interaction between FXIII-A2 and FXIII-B2. These studies aid in

presenting a clearer picture of FXIII-A2B2 heterotetramer formation. A better
understanding of the residues involved in this interaction could potentially be
used to promote either the FXIIIA2B2 formation for prevention of aberrant clotting
or the release of FXIII-A2 for pro-coagulant activity.
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Chapter V
DEVELOPMENT OF A FIBRINOGEN ALPHA-C EXPRESSION SYSTEM
UTILIZING MINIMAL MEDIA AND SUBSEQUENT ALPHA-C STRUCTURAL
ANALYSIS VIA NMR

Introduction
Factor XIII works in concert with thrombin (1Ia) and fibrinogen during the last
steps of the blood coagulation cascade. Fibrinogen (Figure 34) a 340 kDa
protein consists of three chains

A

(Aa, BI3 and y) forming the
homodimer (AaBI3Y)2. The rod-

B

1

like dimer of trimers has a central
E-region which contains the Ntermini of the fibrinogen chains.
The two Aa, BI3 and y chains
extend in opposing directions

Figure 34: Schematic of fibrionogen and the dissociation
of the aC domain when converted to fibrin(102). A. A
Fibrinogen molecule with the D-E-D nodules linked by the
coiled coil connectors and the aC domains interacting with
each other and the central E domain via the B peptides.
Residue 374 has been labeled to give a point of reference .
B. Diagram of a fibrin protofibril where the aC domains
have dissociated after Fbg peptides A and B (marked with
* in A) were cleaved by lIa.

from the E-region in a coiled coil
and terminate in two globular 0regions . Thrombin is responsible
for cleaving fibrinopeptides A and

B (marked with * in Figure 34 A) from the N-termini of the Aa and BI3 chains to
form fibrin I and fibrin II respectively (103) . The resultant fibrin monomers can
align E and D-regions to form a soft clot. Thrombin, as mentioned previously, is
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also responsible for activating FXIII by cleaving the activation peptide at R37G38. Fibrin acts as a cofactor for the activation of FXIII by decreasing the
concentration of Ca 2+ needed for FXIII-A2 to dissociate from FXIII-B2 and also
accelerating the activation peptide cleavage by lIa (29, 31, 74).
The C-terminal portion of the Aa chain extends beyond the D-region to
form the aC-domain (104). The aC-domain (221-610) interacts intramolecularly
with each other and the central E-region of fibrinogen until fibrin assembly.
During assembly, they dissociate from the E-region and interact intermolecularly
promoting lateral aggregation of protofibrils in a process catalyzed by FXIII (105-

107). The process of aggregation begins with v-chain dimerization of fibrin and is
followed by a-chain polymerization (108). The sites of intramolecular crosslinking on the aC-domain are: Gln-Aa-328, Gln-Aa-366, Lys-Aa-508, Lys-Aa-556
and Lys-Aa-562 (109). There are several crystal structures of fibrinogen, but the
aC-domain has been elusive in structural characterization (110-111). The aCdomain, primarily bovine 374 - 538 (human equivalent 392 - 610) has been
studied extensively by NMR. These studies have led to the discovery of a ~
hairpin which is held together by a disulfide linkage C423 - C453 at its base

(102, 112-113). The crosslinking of fibrin monomers by FXIII-A2 is critical to the
formation of stable insoluble clots, yet to date there have not been any studies
exploring the structure of the aC-domain in the presence of FXIII-A2.

Fibrinogen aC-domain (233-425) expression
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In order to monitor the conformational dynamics of the fibrinogen aCdomain in the presence of FXIII-A2, aC-domain (233-425) was expressed in E.
coli. The gene coding for aC (233-425) was cloned into the pGEX-6P-1 vector

which has a glutathione-S-transferase (GST) tag as well as ampicillin resistance.
There were no mutations made to the primary sequence, so the purified DNA
was transformed into DH5a E. coli to create DNA stocks. After collecting DNA
via mini prep, the DNA was subsequently transformed into BL21 Gold (DE3) cells
for protein expression. The BL21 Gold (DE3) competent cells are the suggested
host for pGEX-6P-1 plasm ids.
Once aC expression and purification was confirmed (Figure 35) using
conventional methods (LB broth), a method for protein expression was
developed utilizing minimal media. Minimal media allows for growth with only the
essential nutrients. Providing only the essential nutrients allows for maximizing
the incorporation of isotopic labels

31 .0 kDa
21.5 kDa

not found in standard media. To
enable future studies using NMR, it

14.4 kDa
was imperative to develop a
method of expressing the aC (233425) domain in the presence of
isotopically labeled media

C5 N, 13C

Figure 35: aC Domain (233-425) Purification
Confi rmation . This is a representative PAGE gel
confirming the presence of aC after expression in BL21
Gold cells and purification using GST affinity columns on
an AKTA prime system.

and/or 2H) . Due to the high cost of isotopically labeled nutrient sources, there
have been several methods designed to maximize growth with limited nutrients
(114-116) . The aC domain (233-425) was successfully expressed in BL21-Gold
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cells using a method adapted from Marley et. al and Paliy, et. al with minimal
media containing 15NH4CI (114-115).

NMR methods for analyzing unstructured proteins
Over the past few decades there have been tremendous advancements in
NMR technology allowing for protein analysis. NMR has situated itself at the
forefront as a method of elucidating protein structure, monitoring molecular
dynamics, ligand-receptor interactions, and kinetics (117). To date over 8300
NMR-derived protein structures have been submitted to the Protein Data Bank
(PDB). One benefit to NMR analysis of proteins is the ability to gather structural
information that is not available through contemporary crystallization techniques.
Proteins that do not crystallize well such as membrane bound proteins or
proteins that contain flexible regions (118) that are not visible using X-ray
technology are of particular interest.
Of particular importance in the initiation of protein structural analysis is
the 1D 1H NMR and the 15N-HSQC (Heteronuclear Single-Quantum Correlation)
spectrum (119). The 1D 1H NMR simply displays signals for each proton and the
2D 15N-HSQC shows a unique signal for each proton bound to a 15N. In a 2D
15N-HSQC experiment, the applied magnetization is transferred from any 1H
attached to a 15N nuclei, to the 15N through scalar coupling (J-coupling). The
chemical shift then evolves and is detected after it is transferred back to the 1H
(Figure 36). The resulting 2D spectrum contains a 15N axis and a 1H axis, and
the 1H chemical shifts depend upon the chemical environment (electron density)
surrounding it. Therefore each backbone amide (except proline) gives rise to a
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Figure 36: Representative tripeptide displaying the magnetization transfer during a 15N_HSQC. The
amide Nand H are red to illustrate the atoms involved in the transfer of magnetization . The arrow
indicates the travel of energy from the 1H to the 15N then back to the 1H for detection . The 'CR'
represents the amino acid side chains.

unique resonance at the 15N and 1H frequencies for that individual amide group.
The more shielded the amide is the more its signal will shift upfield and vice
versa . By observing the dispersion of the 15N-HSQC chemical shifts, one can
estimate whether a protein is unstructured or contains any defined structure .
The aC domain (233-425) contains 2 glutamine residues Gln-Aa-328 and
Gln-Aa-366 that are known substrates for FXIII-A2 during blood coagulation.
Prior to transglutmainase activity, the aC domain of fibrin is also known to
associate with FXIII-A2B2. The aC domain is believed to be unstructured in
solution therefore eluding crystallography (40-41). The minimal binding domain
of hypoxia-inducible transcription factor HIF-1a is an example of an unstructured
protein in solution that adopts a structure after it binds, with nM affinity, to CBP
(CREB-binding protein) (118, 120) . This conformational change in HIF-1a is
easily observed through the dispersion of the 15N-HSQC chemical shifts after
addition of CBP to 15N labeled HIF-1a. Using these same techniques the aC
domain (233-425) of fibrin was expressed in minimal media to produce 15N_
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labeled protein. 15N-HSQC was then utilized to monitor peak dispersion
(structure formation) when FXIII-A2 was added to the solution.
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Materials and Methods
Preparation of aC domain (233-425) DNA stocks
The aC-domain (233-425) pGEX-6P-1 plasmid (GE Healthcare,
Piscataway, NJ) DNA was a generous gift from Helen Philippou, Robert Ariens
and Kerrie Smith at the University of Leeds, Leeds Institute of Genetics Health
and Therapeutics (121). It should be noted that all materials used during
transformation, expression and purification were sterile. DH5a E. coli cells
(Invitrogen, Carlsbad, CA) were transformed to build an aC (233-425) DNA
stocks. The first step in transforming the DH5a cells was transferring -5 ng aC
(233-425) DNA into a 50 1-11 aliquot of DH5a competent cells in a 1.5 ml tube.
This DNAIE. coli mix was placed on ice and incubated for 30 min. Following 30
min on ice the cells were heat shocked for 20 seconds in a 42°C water bath and
then returned to the ice for an additional 2 min. The transformation was then
brought to temperature with the addition of 950 1-11 37°C LB media (Appendix C).
The cell mix was then incubated for 1 hr at 37°C while shaking at 225 rpm. After
incubation, if transformation efficiency is low, the cells could be concentrated by
spinning for 2 sec at 10,000 rpm and removing 500 1-11 supernatant prior to
resuspending cells. In most cases this step was unnecessary and 75 1-11 of the
transformed cells were plated on LB agar + Ampicillin plates (Appendix C). The
plates incubated for 16 hr at 37°C. Following transformation, a single intact
colony was utilized to inoculate 4 ml LB agar containing 100 I-Iglml Ampicillin.
The 4 ml culture was incubated at 37°C with shaking at 225 rpm for 16 hr. The
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DNA was then purified using the QIAprep Miniprep kit (Qiagen Inc., Valencia,
CA). Following purification, the DNA concentration was determined using a
Nanodrop ND-1000 Spectrophotometer (Thermo Scientific, Wilmington, DE). A
typical DNA yield for an aC-DNA Miniprep was 60-80 ng/ml. Purified DNA was
also sent for sequencing using pGEX-6P-1 3' and 5' primers (GE Healthcare,
Piscataway, NJ).

Transformation of aC domain (233-425) in BL21 Gold (OE3) cells
Once DNA stocks were established, BL21 Gold (DE3) cells were utilized
to express the aC-domain (233-425) for purification. A 1 - 2 1-11 aliquot totaling 10
- 25 ng DNA was added to a 14 ml round bottom tube with 100 1-11 BL21-Gold
(DE3) E. coli cells (Agilent Technologies, La Jolla, Ca). The BL21 cells were
incubated on ice for 30 min then heat shocked in a water bath for 20 sec at 42°C.
Following the 20 sec heat shock, the cells were placed on ice for additional 2
min. The cells were then brought to temperature through the addition of 1 ml
prewarmed (42°C) SOC media (Appendix C). After addition of SOC media, the
cells (150 1-11) were then plated on LB agar + Ampicillin and incubated overnight at
37°C.
Following incubation, a colony of cells was transferred to 5 ml LB broth
containing 100 I-Ig/ml Ampicillin. The liquid culture was placed in the incubator
where the cells were incubated at 37°C for 16-20 hr and then utilized to establish
BL21-Gold cell stocks. Stocks were made by adding 5 ml 50 % glycerol to the
cells then aliquoting and storing them at -70°C for later use.
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Expressing aC (233-425) in BL21 Gold (OE3) cells

The expression of aC (233-425) in transformed BL21 stocks can take
place in any number of volumes. For example sake the steps used for a 2 L
culture are described. First a 200 ml starter (or seed) culture was grown
overnight after inoculation with the frozen BL21 stocks. The starter culture
consisted of 180 ml LB broth, 20 ml phosphate buffer and 200 1-11 100mg/ml
Ampicillin (Appendix C). The following day prior to addition of cells, 1800 ml
Terrific Broth, 200 ml phosphate buffer and 2 ml 1OOmg/ml Ampicillin was
prepared in a 4 L flask. An aliquot was taken and analyzed on the Cary 50
UVNIS to establish a baseline (Asoo

=0).

Once a baseline was established for T

=0, the 200 ml starter culture was added to the flask.
The culture (2 L) was shaken (225 rpm) at 37°C until the absorbance (cell
growth) A600 = 0.8 - 1.0. At which time 2.2 ml of 1 M Isopropyl

~-D-1-

thiogalactopyranoside (IPTG), a molecular mimic of a lactose metabolite, was
added to the culture. The addition of IPTG triggers lac operon transcription on
the pGEX-6P-1 plasmid leading to the over expression of aC (233-425). After
addition of IPTG, the culture was shaken (180 rpm) at 30°C for 16 hours. The
cells were then transferred to centrifuge bottles and harvested during sequential
10 min spins at 5000 g and 4°C. The harvested cell pellets were resuspended in
180 ml ice cold E. coli wash buffer (Appendix C) by stirring (800 rpm) for -40
min. Lastly, the cell suspension was transferred to 50 ml conical tubes and
centrifuged in a swinging bucket rotor 45 min at 5000 g and 4°C. The
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supernatant was discarded and the cell pellets were placed at -20°C until
purification.
Expressing 15N_aC (233-425) in BL21 Gold (OE3) cells with Minimal Media

For isotopically labeling aC (233-425) the transformed BL21 cells were
grown in minimal media. The recipes used for M9 salts and M9 media were
adapted from Marley et al. and Paliy, et al (114-115). The seed culture for
minimal media expression was grown in standard LB broth. For a 2 L culture,
two sterile 50 ml conical tubes containing 36 ml LB broth were inoculated with the
frozen stocks of transformed BL21 cells. The starter culture was grown overnight
at 37°C while shaking at 225 rpm. The following morning the two starter cultures
were spun at 5000 g for 10 min and the LB broth was discarded. Being careful
not to disturb the
pellet, the pellet was

Table 5: Components of 1 L 5x M9 salts and 1x concentration. The
mass needed for 1 L 5x M9 salts and the final salt concentration after
dilution to 1x.

washed 2x with 5 ml
1X M9 salts (Table

Mass (9)

1 x (mM)

30

44

108
2.5
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KH 2 P04
Na2HP04
NaCI

9

5). The pellet was
then resuspended in 2 ml1 x M9 salts and transferred to 2 L of M9 media (Table
5 and Table 6). Prior to addition of cells to the M9 media, an aliquot was taken
and used to establish an

A600

baseline. Cell growth was monitored and the cells

were induced with the addition of 2 ml 1 M IPTG. The cells were then incubated
overnight at 30°C while shaking at 180 rpm. The 2 L culture was then spun
down, washed and spun down again before freezing in the same manner
previously described for growth in LB broth.
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Table 6: Recipe for M9 minimal media. This table outlines all the components added to 1
L of M9 growth media. For each component, the volume added as well as the final
concentration are given.

Volume (ml)
200
1.00
1.00
4.00
0.05
1.00
40.0
753

M9 Media component
5x M9 salts
1 M MgS04
200 mM CaCI 2
aO.25 g/ml NH 4 CI
20 % Thiamine HCI
100 mg/ml Ampicillin
20 % Dextrose
Sterile dH 20

Final Concentration
1x
1.0mM
0.2 mM
1.0 gil
0.001 %
0.1 mg/ml
0.8%

a For expressing isotopically labeled proteins, 15NH4CI was utilized as opposed to NH 4 CI.

Purification of aC (233-425)
The aC (233-425) produced during growth in LB media or M9 media was
purified using the same process. Hot water was run over tubes and a spatula
utilized to help transfer the frozen pellets to a clean 500 ml beaker. The tubes
were rinsed with and resuspended in ice cold PBS (4 ml PBS/100 ml culture - 88
ml PBS for 2L). The cells were stirred gently at room temperature to resuspend.
Once resuspended, 888 1-11100 mglml Lysozyme [1 mg/ml] (the [] indicate assay
concentration) and 88.8 1-111 M OTT [1 mM] was added to the cell suspension
and incubated at room temperature, stirring gently, for 30 min. The protease
inhibitors listed in Table 7 were added to the cell suspension and incubated for
30 min at 4 °C stirring gently. Following incubation with protease inhibitors, 222 1-11
100 mM phenylmethylsulfonyl fluoride [0.5 mM] and 449 1-11 10% Sodium
Deoxycholate were added and the cell mix was stirred for 30 more minutes. The
addition of 20% Triton X100 [1%] was done forcefully then 47.3 1-1110mg/ml
DNase 1 [5 I-Ig/ml] was introduced with 472.5 1-11 1 M MgCI 2 [5 mM). This was
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Table 7: The protease inhibitors utilized in during purification of recombinant protein.

Added to 2 L
Culture
88.9 IJI
88.9 IJI
222 IJI

0.069 9

Protease Inhibitor

Assay Concentration

2 mg/ml Aprotinin
1 mM Pepstatin A
4 M Leupeptin
Benzamidine

[2 IJg/ml]

[1 IJM]
[10 IJM]
[4 mM]

incubated for 10 min at 4°C with stirring then quenched with the addition of 1.15
ml 0.5 M EDTA [6 mM]. The cell suspension was then transferred to centrifuge
tubes and spun for 20 minutes at 22,000 g. The supernatant was filtered using
0.22 IJm Supor machV 150 ml filter-flasks (Nalgene, Rochester, NY).
The purification process takes advantage of GST that is co-expressed with
the aC (233 - 425). Utilizing an AKTA prime system, with GST specific
GSTrapTM HP Columns (GE Healthcare, Piscataway, NJ) the GST-aC was
trapped on the column (Figure 37). After overnight digestion with PreScission
Protease, 1 unit per 100 IJg protein, (GE Healthcare, Piscataway, NJ) the free aC
(233 - 425) was eluted from the column. To ensure a clean sample for future
NMR studies the unlabeled aC (233 - 425) product was cleaned using a
Detergent Removal Spin Column (Pierce, Rockford, IL). The 15N aC (233 - 425)
was dialyzed into 1 x PBS and all recombinant aC was concentrated using an
Amicon Ultra centrifugal concentration devices MWCO

=10,000 (Millipore,

Billerica, MA). The concentration was established using an extinction coefficient
of 41 ,480 M- 1 cm- 1 calculated using ExPASy ProtParam
(http://web.expasy.org/protparam/).
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Figure 37: Visualization of aC (233-425) purification following expression in BL21 Gold E. coli cells .
A)

There are two different schemes shown ; one for eluting aC (233-425) still bound to the GST
linker (steps 2 - 4), and the other describes an on column digest to elute just aC (233-425) from
the GSTrap column (steps 5 - 9). Step (1) is the addition of cell lysate to the GSTrap (GST
affinity column) . For elution of the GST- aC conjugate, the column was rinsed (2) , and reduced
glutathione is pumped across the column (3) releasing the GST-aC from the glutathionesepharose column material. The GST-aC (233-425) fraction is collected and stored at 4 · C until
further analysis (4) . For on-column digests, after the addition of cell lysate the column was rinsed
(5). PreScission protease was then added to the column (6) and allowed to incubate at 4 · C
overnight (7). The following morning an additional GSTrap column was added to capture any
possible GST that may be released (8) and the recombinant aC (233-425) was eluted and stored
at 4 · C until further analysis (9).

B)

Representative SDS-PAGE gel and Western Blot image. In the SDS-PAGE gel the green band
represents aC (233-425) and the pink band GST- aC (233-425). The GST specific Western Blot
is representative of a blot containing un-cleaved GST- aC (233-425).

Adapted from GST Gene Fusion System Handbook (122)
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SDS-PAGE and Western Blot
All expression products were confirmed using SOS-PAGE. The 15 % resolving
gel was prepared by combining 2.4 ml dH20, 2.5 ml 1.5 M Tris (pH = 8.8), 5.0 ml
30 % acrylamide and 0.1 ml 10 % SOS. The acrylamide polymerization was
initiated with the addition of 50 1-11 Ammonium Persulfate (APS) and 5.0 1-11
Tetramethylethylenediamine (TEMEO). The 4.0 % stacking gel which was
poured on top of the resolving gel consisted of: 6.1 ml dH20, 2.5 ml 0.5 M Tris
(pH = 6.8), 1.3 ml 30 % acrylamide and 0.1 ml 10 % SOS. Once again, the
polymerization was initiated with 50 1-11 APS and 10 1-11 TEMEO. Samples were
mixed with non-reducing sample buffer. The Bio-Rad MiniGels (Hercules, CA)
were run at 200 V for 1 hr. The PAGE gel was then either subjected to Western
Blot or Coomassie Blue (0.1 % Coomassie Blue, 40 % MeOH, 10 % Acetic Acid
and 50 % dH 20) staining. For staining, gels were placed in Coomassie Blue
stain overnight then destained for approximately 3 hours in Oestain (40 % MeOH,
10 % Acetic Acid and 50 % dH 20). Gels were then imaged using a Gel OOC™
XR+ System (Bio-Rad, Hercules, CA).
After SOS-PAGE, western blots were utilized to confirm the presence of
GST - aC (233 - 245) or determine whether all GST was removed after oncolumn PreScission protease digestion. The gel, fiber pad, filter paper, and
nitrocellulose membrane (NitroBind, Osmonics Inc.) were equilibrated by soaking
them in the Western Blot Transfer Buffer (25 mM Tris, 192 mM Glycine and 20 %
MeOH pH=8.3) for 15-20 min at room temperature. The Mini Trans-Blot (Bio-
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Rad Hercules, CA) was loaded as per instructions and run at 100 V for 1 Hr at 4
DC. To decrease non-specific binding, the nitrocellulose membrane was placed
in a 3 % BSA Blocking Solution in PBST with stirring overnight at room
temperature. The following morning, the membrane was washed in PBST then
placed in a solution containing 1:5000 a-GST-HRP (horseradish peroxidase) (GE
Healthcare, Piscataway, NJ). After a series of 5 rinses in 1x PBST, the
membrane was developed using 1-Step TMB-Blotting solution, a blue TMB
(3,3',5,5'-tetramethylbenzidine) peroxidase which is an HRP substrate (Pierce,
Rockford, IL). Membranes were then dried and visualized on the Gel OOC™ XR+
System (Bio-Rad, Hercules, CA).

15N_1H HSQC
After the 15N labeled and unlabeled aC domain (233 - 425) were dialyzed
and concentrated, they were loaded into NMR Shigemi tubes. The concentration
in the NMR ranged from < 100 I-IM for the unlabeled aC domain (233 - 425) to >
200 I-IM for the 15N labeled material and all samples were run in the presence of
10 % 0 20. The pH of NMR samples was not adjusted below 6.6 due to a
theoretical pi of 6.28 (http://web.expasy.org/protparam/). Two NMR experiments
were run to establish the feasibility of determining aC domain (233 - 425)
structure. aC domain (233 - 425) was first analyzed with a Watergate 1HTOSCY and then the 15N_aC domain (233 - 425) was utilized in 15N_1H HSQC.
To determine if the aC domain (233 - 425) adopts a defined compact structure in
the presence of FXIII-A2 a 15N_1H HSQC was performed. For this analysis, 350
1-11 of 210 I-IM 15N aC (233 - 425) was used to solubilize 3.2 mg dialyzed and

lyophilized FXIII-A2. The final concentrations in the NMR tube were 110 I-IM
103

FXIII-A2 and 210 IJM 15N aC (233 - 425). All NMR experiments were performed
on a 16.4 Tesla 700 Varian Inova MHz NMR or an 18.8 Tesla 800 MHz Varian
Inova NMR.
The NMR data shown in Chapter V were collected on the Varian Inova
800 MHz spectrometer which is equipped with a triple resonance probe and
pulsed-field triple axis gradients. 1H - 15N HSQC experiments were run on the
15N aC (233-425) in the absence and presence of unlabeled FXIII A 2. For both
systems, the 1H frequency was 799.708 Hz and the sweep width was set at
12000 whereas the 15N frequency was 81.043 Hz and the sweep width was set at
2300. Spectra were collected with 1800 complex points in the 1H dimension and
100 increments in the 15N dimension. The number of transients was 8. All HSQC
experiments were run at 20°C and water was used as a reference. The NMR
data were processed using NMRPipe and NMRDraw version 6.5 (123) and the
results visualized using Sparky version 3.1 (124). The ppm reference for the
center of both 20 spectra was 4.821 ppm and 119.990 ppm. Sparky was also
used to overlay the HSQC spectrum of 15N aC (233-425) on to the spectrum of
the protein-protein complex involving 15N aC (233-425) and FXIII A 2. The Overlay
Views dialog box was used. Both spectra had been subjected to the same
experimental parameters, referencing, and data processing strategies.
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Results
aC (233 - 425) Expression in LB Broth
To establish an expression system in the lab two systems were chosen for
method development, FXIII-A2 and aC (233 - 425) . The aC (233-425) gene was
cloned into pGEX-6P-1 vectors (Figu re 38) . The location of the aC gene insert
was ideal for PreScission protesase cleavage and GST cleavage during
pu rification .
The first objective was to transform the cloned pGEX-6P-1 vector into

Elem,=nt:12
Mn f()NIard20 primer
Element#11
M13 pUC rev primer
Elememt#1 0
lac promoter

--

Element#1
tac promoter
ElSm&ntt2
·113 pUC rev pnmer
Element#3 -

~

pGEX·5' primer
GSHag

lacl

pGEX-6P-1
5553bp

Element#4
pGEX_3_pnmer
Element#5
_AmpR_p rolTloter
~

Elemen ~
Figure 38: Map of pGEX-6P· 1 vector. Elements of interest are labeled . The elements to note are the
tacJ)romotor (Orange) , GST-tag which contains the pGEX-5' primer (Blue) , alpha_C gene (Red) .
pGEX_3_primer and the Ampicillin gene (Purple) . Image created using DNA 2.0 Gene Designer 2.0 software .
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DH5a cells in order to build a series of DNA stocks. Using the transformation
methods set forth by Smith et. al., the DNA yields from a standard MiniPrep were
consistently 60-80 ng/ml (121). This allowed for the storage of several DNA
aliquots to be used in future studies. To confirm that the purified DNA contained
the aC (233 - 425) gene, it was sequenced using the pGEX-6P-1 3' and 5'
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Figure 39: Alignment of 3' primer sequence data (top) and aC (233 - 425) gene sequence (bottom) .

primers (3' CCGGGAGCTGCATGTGTCAGAGG and 5'
GGGCTGGCAAGCCACGTTTGGTG) (Figure 38). Both the 5' and 3' primers
produced sequence data that confirmed the entire aC (233 - 245) construct
sequence (Figure 39) . The two mis-hits (nucleotide 297 and 300) in Figure 39
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were both mutations that did not lead to a change in amino acid. The G to A
(GG(A)) mutation at nucleotide 297 remains a glycine and the C to T (AG(T))
mutation at nucleotide 300 remains a serine.
Initially, protein expression took place in standard LB media. The DNA
collected from DH5a cells was successfully transformed into BL21 Gold (DE3)
cells. During the first attempts at collecting purified protein from a 2 L culture, the
decision was made to elute the uncleaved GST-aC (233 - 425) from the GSTrap
column. The next step was developing a method to release the GST from the aC
(233 - 425). This was done via an on-colum n digest (Figure 37) which utilized
PreScission protease. PreScission protease selectively cleaves between Gin
and Gly in a sequence (Leu Glu Val Leu Phe Gin I Gly Pro) found N-terminally to
aC (233 - 425) . Therefore, after
transformation and purification the cell

2

extract was loaded on the GSTrap column
and then the column was removed from

3

4

5

6

75 kDa

50 kDa
37 kDa

the AKTAprime system. At which time
PreScission protease was added and
incubated on-column overnight at 4

°c to

20 kDa

allow for cleavage between aC (233 - 425)
MW = 19582 g/mol and GST MW =27,000
g/mol. The GST and GST-tagged
PreScission protesase remain on the
columan and the cleaved aC (233 - 425)
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Figure 40: Representative GST specific
Western Blot. Lane (1) was collected from
the waste line while loading the column with
cell extract. (2) was the cell extract. (3) was
the concentrated aC product with GST
contaminant. (4) was the ladder. (5 and 6)
were collected during GST elution .

was eluted the following morning . SOS-PAGE and a GST-specific western blot
were run to evaluate the expression and purification process (Figure 40). The
GST-specific western blot exposed that GST was eluting with the aC (233 - 425) ;
therefore, in future protein elutions an additional GSTrap column was added post
on-column digestion to sequester any GST that may be co-eluting with aC (233 425) .
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Figure 41: Representative SOS-PAGE and western blot confirming proper aC (233 - 425) purification
and GST cleavage. (A) The first three wells in the SOS-PAGE illustrate the aC (233 - 425) was
sufficiently cleaved and eluted. The GST elution illustrated in wells 5 - 7 demonstrated minimal residual
aC (233 - 425) . This carryover was not affected by increasing the column wash-time/volume between
aC (233 - 425) and GST elution. (8) Wells 1 - 3 of the GST-specific western blot demonstrated a clean
aC (233 - 425) elution free from GST. Wells 5 - 7 contain the cleaved GST fraction .

Expresssion in minimal media

Expression in minimal media proved to be just as successful as aC (233 425) expression in under standard nutrient conditions. The true yields of both LB
and minimal media expressions are difficult to report due to loss of material
during storage , dialysis, and surfactant removal but both methods were
successful in producing enough protein for NMR analysis. During minimal media
expression and purification , the GST that had eluted with purified aC (233 - 425)
previously was eliminated (Figure 41 B). One issue that did occur in all
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expressions was mild carryover after aC (233 - 425) elution. The aC (233 - 425)
that eluted with the GST was seen as a faint band around 20 kDa in the GST
fractions (Figure 41A). This band occurred even after increasing the column
wash time following aC (233 - 425) elution. Another possible issue is the band in
the western blot around 45 kDa. This could possibly be conjugated GST-aC (mw

=46,582 kDa).

If that were the case, additional PreScission protease should

yield more aC (233 - 425) and decrease the intensity of the band at 45 kDa. This
was attempted and the 45 kDa band was still quite prominent; therefore, the
large band around 45 kDa may be due to non-specific binding. The aC (233 425) expression system proved to be quite versatile and allowed for protein
production under standard nutrient conditions and under minimal media with 15N_
NH 4CI.

aC (233 - 425) 15N-HSQC
Although the ultimate goal of expressing aC (233 - 425) in 15N-labeled
minimal media was to enable NMR observations, the first NMR experiments
utilized unlabeled aC (233 - 425). A valuable lesson was learned during our first
TOSCY analysis of unlabeled aC (233 - 425). There was substantial
contamination from a small molecule in our sample. After reviewing the
purification procedures, the problem was identified as Triton X-100 which is
added to help solubilize the protein before centrifugation. The Triton X-100
concentration is 1 % and the critical micelle concentration is 0.1 %. The Triton X100 micelles contain 628 Triton units/micelle therefore has an apparent
molecular weight of -90 kDa. This apparent molecular weight caused the Triton
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Figure 42: 15N_HSQC spectra of 15N_aC (233-425) conducted on an 800 MHz (18 T) Varian Inova NMR at
20 °C. The assignments can be viewd in appendix F.

X-100 to concentrate with our protein of interest. In order to thwart this problem
in the future two different techniques were utilized , 10,000 MWCO dialysis into 1
x PBS and/or Detergent Removal Spin Columns .

The first 15N-HSQC spectra for 15N_ aC (233 - 425) were attained on a
16.4 T Varian NMR equipped with a triple resonance cryoprobe and confirmed on
the 18 T Varian NMR (Figure 42) . The concentration of aC (233 - 425) was 210
IJM and pH

=6.6.

As this was an aqueous sample, Watergate was utilized for

water suppression . These experiments prove that even at sub mM
concentrations of aC (233 - 425) one can still observe the 1H_15N-HSQC
transitions. aC (233 - 425) contains 193 residues, 17 of which are proline, so
therefore there are 176 amide hydrogens. In addition to the amide backbone,
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there are 13 asparagines, 3 glutamines (each with two proton signals for the
same nitrogen) and 7 tryptophans. Therefore, there should be a total of 199
observable 15N_1H signals. The aC (233 - 425) 15N-HSQC successfully identified
approximately 184 of the 199 possible signals (Appendix F) . Of the 7 Trp all but
one was visible and 13 of the 19 Asn and Gin were visible .
Once an HSQC for aC (233 - 425) was established, the next goal was to
observe aC (233 - 425) in the presence of FXIII-A2 (Figure 43). The same 210
!-1M aC (233 - 425) sample used previously was utilized to solubilize 3.2 mg
FXIII-A2. The sample precipitated out of solution and sonication for 5 min at
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Figure 43: 15N_HSQC spectra of 15N_aC (233-425) in the presence of FXIII-A2 conducted at 20 · C on an
800 MHz (18 T) Varian Inova NMR. The assignments can be viewed in Appendix G.
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room temperature did not increase solubility. The pH of the aC (233 - 425) FXIII-A2 solution was confirmed to be 6.6 and was spun at 14,000 rpm. The
supernatant was then transferred to a Shigemi tube for NMR analysis. Due to
precipitation and analysis of the supernatant the final concentration of aC and
FXIII-A2 was unknown, but assumed to be less than the starting concentrations
(210

~M

and 110

~M

respectively). The structure of aC (233 - 425) in the

presence of FXIII-A2 was also investigated using an 18 T Varian NMR. When
aligned with the 15N_aC (233 - 425) 1H_15N_HSQC, 15N_aC (233 - 425) with FXIIIA2 did not exhibit any major peak shifts but several new peaks appeared. In the
HSQC for aC (233 - 425) in the presence of FXIII-A2, approximately 191 of the
199 possible N-H stretches were observed (Appendix G). This was an increase
of 7 over the 184 signals observed for aC (233 - 425). The most notable new
peaks are at (N-120.7 ppm, H-8.68 ppm) and (N-121.8 ppm, H-8.36 ppm) as well
as the Trp residue (N-129.7 ppm, H-10.15 ppm). It is quite promising to see that
even under conditions where some material may have been lost during
precipitation, aC (233 - 425) still appears to gain some structure when in the
presence of FXIII-A2.
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Discussion
Many kinetic and conformational dynamic studies require specific
mutations. Thus it is imperative to establish and maintain functional expression
systems. The aC (233 - 425) DNA that was given to our lab has now been
successfully transformed into both DH5a and BL21 DE3 (gold) E. coli cells. The
transformed DNA was then utilized to express and purify aC (233 - 425) for 15N_
HSQC NMR analysis.
aC (233 - 425) Expression

The DNA utilized had the aC (233 - 425) gene cloned into a pGEX-6P-1
vector. The pGEX-6P-1 vector has several benefits. Expression of aC (233 425) in the pGEX-6P-1 vector is induced with IPTG. aC (233 - 425) expression
is under the control of the tac promoter which is induced by IPTG, a lactose
mimic. The pGEX-6P-1 plasmid also contains a lacf1 gene which produces a
repressor for the tac gene inhibiting expression untillPTG is added. To ease in
protein purification following expression, the protein of interest is co-expressed
with a GST tag. The GST tag is then subsequently utilized in affinity
chromatography to capture the GST-aC product. Another benefit of the pGEX6P-1 is that it contains an Ampicillin resistance gene to assist in confirming
transformation in your cells of interest.
Two different cell lines were chosen for aC expression, the first of which
was DH5a. The DH5a cells chosen were the Subcloning Efficiency Competent
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Cells which allowed for an efficient transformation and subsequent production of
purified DNA for future transformations. One lesson learned during this process
was that if the transformation does not produce nice round colonies and the
plates are covered with a lawn of E coli, the Ampicillin may have expired.
According to Ryan, et al. Ampicillin starts to lose activity after 30 days at 4 °C
(125). Following expression in DH5a cells the DNA that had been successfully
purified was transformed into BL21 cells for aC (233 - 425) expression and
purification.
The E coli strain BL21 gold (DE3) is frequently used as a host for protein
expression studies. Bhandari and Gowrishankar reported on the robustness of
the BL21 gold expression options (126). BL21 cells also limit the degradation of
expressed proteins because they naturally lack genes for the proteases Ion and
ompT (127). Although transformation efficiency was never calculated, a nice

selection of colonies was always observed. The reported efficiency for pUC18
DNA is ~ 1 x 108 cfu (colony forming units)/lJg of DNA (Stratagene, La Jolla, CA).
Once transformed into the BL21 gold cells, selected colonies were then
grown in liquid LB broth to create glycerol stocks of cells ready for aC (233 425) expression. The glycerol stocks were stored at -70°C and a sterile loop
was utilized to seed cultures for expression. After an overnight incubation, the
starter culture was utilized to seed a larger (1-2 L) culture. There are several
variables which are critical to maximizing the amount of aC (233 - 425)
expressed, one of which is the proper cell density for induction. During log
phase, the doubling time of Ecoli is typically between 20 - 30 min in nutrient rich
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media. It is during this time that cells are in the optimal condition for expressing
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Figure 44: Theoretical E. coli growth curve. Lag phase displays the slow growth after inoculation.
During Log Phase, the cell doubling time is around 20 - 30 min. This is the optimal time for induction of
protein expression. During stationary phase, nutrients are limited, cells become stressed and protein
degradation can occur. During death phase cells begin to die due to lack of nutrients and cell density
decreased over time.

protein (Figure 41) . During LB broth , nutrient rich , expressions the cells were
induced at A 600 = 1.0 and 0.6 for the minimal media expressions. The slope
during log phase decreased from 0.54 A 6oo /hour for growth in nutrient rich media
to 0.20 A 6oo /hour in minimal media. This> 2.5 fold decrease in slope led to much
longer incubation times prior to induction for the minimal media expressions.
To ensure induction during log phase, the induction for minimal media
took place at A 600 = 0.6 since nutrient rich growth appears to be approaching
stationary phase when A 600

= 1.0 (Figure 42) .

After IPTG addition both nutrient

rich and minimal media cultures were allowed to incubate overnight at 30

ac.

This is another variable which cou ld possibly be optimized. By decreasing the
rpm of the shaker from 225 to 180 rpm and decreasing the temperature from 37
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°C to 30 °C, it slows the growth. It may be worth investigating shorter induction
periods at 37 °C and 225 rpm. The last issue concerning expression which was

1.2

•

LB Broth

•

1.0
y = 0.5351x-0.182

•

8 0 .8
~

•

>-

Minimal Media

."(/)
'=

c 0.6

y = 0.202x- 0.8346 •

Q)

o

Q5

o

0.4

• •
0.2

•
•

O ~----~------~----~----~------~----~------~----~

o

2

345

Time (hou rs)

6

7

8

Figure 45: Representative growth curves for BL21 gold (OE3) cells grown in LB broth and minimal
media. LB Broth is represented by the (Red Squares) and the time points utilized for calculating the
slope of the Log Phase are marked with a black (X) . The minimal media growth curve is represented by
(blue diamonds) and the time points utilized for calculating the slope of the Log Phase are marked with a
black (X) .

overcome involved the use of Triton-1 00 during the purification process. When
viewing the first aC (233 - 425) NMR Triton X100 was the only molecule visible.
The Triton X100 was concentrated when using 10,000 MWCO centrifuge
concentrators to purify the aC (233 - 425) . To thwart this in future aC (233 425) expressions, both detergent removal spin columns and dialysis were utilized
successfully. Further experimentation could be performed to determine which
process is the most effective.
aC (233 - 425) 15N_HSQC
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It was first reported in 1981 that the 242-424 region of the fibrinogen achain was involved in reducing the concentration of Ca 2+ needed for FXIII-A2 to
dissociate from FXIII-B2 (74). Until recently very little research has been
dedicated to further investigating this interaction between the aC-domain (Cterminal portion of the fibrin a-chain) and FXIII-A2. There have been a series of
manuscripts which have focused on determining whether bovine and/or human
aC-domain contains compact structure (102, 113, 128). Burton et al. utilized
NMR to identify and characterize a

~-hairpin

with a disulfide (C423-C453)

restricting the base in bovine aC (374 - 538) (102). The

~-hairpin

was then

further characterized with a shorter aC fragment (406 - 483) focusing in on the
compact structure (113). During this study aC (406 - 483) was fully
characterized by NMR which allowed for the identification of a second loose

~

hairpin that is formed by residues 459 - 476. It was also determined by size
exclusion chromatography and analytical ultracentrifugation that the aC (406 483) fragment formed oligomers in a concentration dependant manner, starting
at concentrations as low as 3 mg/ml (113).
More recently, the knowledge gained from investigating the structure of
bovine aC has been utilized to better understand human aC structure. It was
determined that human aC (425 - 503) and (392 - 610) form oligomers as a
function of concentration like their bovine counterparts (128). The NMR analysis
of human aC (425 - 503), equivalent to bovine (406 - 483), was limited due to
the oligomerization. Since bovine aC (406 - 483) had been fully characterized,
the human aC 15N_HSQC was compared to the bovine. This comparison
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revealed that human aC (425 - 503) contained several of the same peakes that
were essential for l3-hairpin formation in bovine aC (113, 128).
These human aC structural studies utilizing NMR have yet to describe
how aC interacts with FXIII. Smith et al. has extensively studied the human aC
(233 - 425) fragment and how it interacts with unactivated FXIII-A2, activated
FXIII-A2 and FXIII-A2B2 (121) . Surface plasmon resonance (SPR) was used to
study a series of truncated aC fragments and it was determined that activated
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Figure 46: 15N_HSQC spectra of 15N_aC (233-425) overlaid on the spectra for 15 N_aC (233-425) in the
presence of FXIII-A2. The 15N_HSQC spectrum for aC (233-425) is displayed in ~Iue) and aC (233-425) in
the presence of FXIII-A2 in (pink) . The three peaks noted are only visible in the 1 N-HSQC spectra for aC
(233-425) with FXIII-A2.The image was produced using the overlay command within Sparky 3 (124) .

FXIII-A2 had low !-1M affinity for aC and it was localized to residues 389 - 403.
FXIII- A2B2 was found to have low nM affinity and surprisingly, FXIII-A2 zymogen
did not bind to any of the aC fragments (121). The 15N-HSQC data reported here
investigates aC (233 - 425) both in the presence and absence of FXIII-A2
zymogen. After the addition of aC to the lyophilized FXIII-A2 there was a
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substantial amount of precipitate formed. It is unknown whether the precipitate
correlates to aC oligomerization or possible aC-FXIII-A2 interactions. The
sample for aC with FXIII-A2 15N-HSQC analysis had to be spun down and only
the supernatant was analyzed. The increase in total peaks identified for the aC
(233 - 425) with FXIII-A2, as seen in the overlay of the two spectra, alludes to an
interaction that induces structure in aC (Figure 46). Our lab has now established
an aC (233 - 425) expression system in standard media as well as minimal
media capable of producing enough protein for NMR analysis. These NMR
studies have now opened the door to further investigation of aC (233 - 425) in
the presence of FXIII-A2.
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CHAPTER VI
CONCLUSIONS AND FUTURE DIRECTIONS
Factor XIII is one of the last enzymes involved in the blood coagulation
cascade and is responsible for cross-linking fibrin monomers to form an insoluble
clot. Through the utilization of HDX coupled with MALDI-TOF MS, great strides
have been made in clarifying FXIII-A2 conformational dynamics during activation.
The importance of FXIII during haemostasis has led to increased interest in
acquiring a greater understanding of how this enzyme interacts with its
substrates and cofactors in solution. Therefore, in addition to studying FXIII,
NMR was utilized to investigate the FXIII-A2 substrate fibrin aC (233-425).
The conformational dynamics of Factor XIII-A2 (zymogen, FXllla lla ,
FXllla ca , and inhibited with Kg-Don) in solution has been extensively studied
using HDX (43, 45-46). One area that lacked understanding was how the FXIIIA2 structure was dependent upon physiological Ca 2+ concentrations. Chapter II
describes the first objective of this project; to investigate the conformational
dynamics of FXIII-A2 under physiological Ca 2+ concentrations and compare to
other metals of interest (Mg 2+, 8a 2+, and Cu 2+). HDX analysis identified regions
of FXIII-A2 where Ca 2+ elicited unique conformational differences when compared
to the other metals studied. There were also several regions of FXIII-A2 where all
metals examined yielded similar conformational changes. Due to the similarities
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observed for these metals, they were then tested to determine whether they
could promote non -proteolytic FXIII-A2 activity.
In addition to studying FXIII-A2 non-proteolytic activation in the presence
of 50 mM Ca 2+, Mg 2+, 8a 2+ and Cu 2+, we also investigated 500 mM Na+ and two
organic cations EDA2+ and TMAC+. When investigating each cation individually
only 50 mM Ca 2+ could promote FXIII-A2 activity. The cations Mg2+, 8a 2+, Na+,
EDA2+ and TMAC+ all induced FXIII-A2 activity when in the presence of 2 mM
Ca 2+. Low mM Ca 2+ was essential for non-proteolytic activation. The activity
observed using organic cations (EDA2+ and TMAC+) revealed that non-proteolytic
activation is not unique to metal ions (44). HDX analysis was then utilized to
study the conformational dynamics of non-proteolytically activated FXIII-A2.
These analyses revealed that exposure around the active site and substrate
recognition regions was initiated by physiological Ca 2+ concentrations and set the
stage for the larger conformational changes observed after activation.
While working on the FXIII-A2 conformational dynamics presented in
Chapter II, Pinkas et al. reported that TG2 is trapped in an open conformation
when bound to a substrate-based inhibitor (49). It has been debated whether
FXIII-A2 undergoes a similar conformational change; therefore, in Chapter III
HDX was utilized to compare the solvent accessibility of TG2 zymogen to that of
activated TG2 and also inhibited TG2. Evidence of the open conformation was
observed as increased exposure on the p-barrels and regions of the catalytic
core. When comparing FXIII-A2 to the open conformation of TG2 it becomes
obvious that in order to exist in an open conformation, FXIII-A2 must overcome
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substantial steric strain between the

~-sandwich

of one FXIII-A2 monomer and

~

barrel 2 of the opposing monomer. If FXIII-A2 does adopt an open conformation,
it could lead to further developments in pharmaceuticals and antibodies specific
for the open conformation which could be utilized in correcting aberrant FXIII-A
during coagulation.
In regards to comparing TG2 and FXIII-A2 conformational dynamics, future
work could take a few directions. Y238C FXIII, a physiological mutant, is a
monomer. Now that our lab has established expression systems, it may be
possible to express FXIII-A Y283C and compare FXIII-A in the monomer form to
TG2. The Y283C monomer would be utilized because, as mentioned in Chapter
III, the 'open' conformation seen in TG2 may be sterically impossible for the
FXIII-A2 dimer. Although the Y283C mutant is physiological, it is not stable in
whole plasma, having a shorter

t1l2

than wild type FXIII (99). If the Y283C mutant

shows promise, mutation of the homologous TG2 residues may create a stable
monomer, which one day might be used as a therapeutic for FXIII deficiency and
thus combat postoperative bleeding
After exploring FXIII-A2 during activation and comparing FXIII-A2 to the
open versus closed conformation for TG2, our focus shifted in Chapter IV to the
conformational dynamics of FXIII-A2 bound to FXIII-B2 but before activation. It
has been proposed that the two

~-barrels

of FXIII-A2 interact with FXIII-B2 in the

heterotetramer since heterotetramer formation does not occur when the

~-barrels

are truncated (99). This evidence is supported by the significant protection from
HDX observed in the

~-barrels.

If the FXIII-B2 dimer assumes the structure
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proposed by Souri, et 81. its length would be> 380

A (98). The FXIII-A2 structure

is only 102 A in length, and therefore, protection was observed throughout FXIIIA 2. One FXIII-A2 region of interest during activation, the dimer interface,
becomes significantly protected when bound to FXIII-B2, which would limit FXIIIA2 activation.
To further investigate the FXIII-A2B2 heterotetramer, a more intensive HDX
method could be performed. Our MALDI-TOF MS method works well, but
increased sensitivity and increased sequence coverage is observed using LCICR-MS (129-130). Develop an HDX method on an LC-FT-ICR-MS would open
many new doors. Historically, LC methods were avoided during HDX
experimentation due to increased hydrogen back-exchange during the aqueous
separation prior to MS detection. This problem is now avoided by keeping the
column and transfer lines chilled to 0 °C and also the advances in LC and column
technology that have led to shorter run times (1 min). One factor limiting HDX
with MALDI-TOF-MS detection is the mass of the protein and number of proteins
being analyzed due to the increase in peptides produced and the inability to
distinguish them. A liquid chromatography separation of peptides prior to MS
detection allows for the identification of peptides of similar mass that overlap in a
MALDI-MS.
Now that the regions of FXIII-A2 which contact FXIII-B2 in the FXIII-A2B2
heterotetramer have been established, it would be of interest to utilize NMR to
determine the regions of aC(233 - 425) that contact on FXIII-A2B2. The aC(233
- 425) region is involved in the dissociation of FXIII-A2 and FXIII-B2, and may
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adopt a unique conformation when interacting with the FXIII-A2B2 heterotetramer.
It would be nice to compare the analysis of aC(233 - 425) in the presence of
FXIII-A2B2 to the results reported in chapter V for aC(233 - 425) in the presence
of FXIII-A2.
Lastly, in chapter V, a method was established for expressing aC (233 425) in both standard LB broth for bulk protein production and minimal media for
isotopically labeling the protein to enable NMR analysis. The aC (233 - 425)
domain was chosen because of its known involvement in fibrin crosslinking by
FXIII-A2. Not only does aC (233 - 425) contain 3 FXIII-A2 Gin substrate
residues, it also acts as a cofactor in the dissociation of FXIII-A2B2 as well (74,

109). The aC (233 - 425) region is largely unstructured and has yet to be
visualized via crystallography (110-111).
In an attempt to determine if the aC (233 - 425) region adopts a compact
structure when interacting with FXIII-A2, 15N_aC (233 - 425) was expressed in
minimal medial and subjected to 15N-HSQC NMR analysis. An increase in the
total number of peaks indicates that the interaction between aC (233 - 425) and
FXIII-A2 induces a more structured aC. While these NMR studies were being
developed, Smith et al. used SPR techniques, to demonstrate that aC (233 425) has low nM affinity for FXIII-A2B2 and FXllla but does not interact with FXIIIA2 zymogen (121). These results lead to the question of whether aC (233 - 425)
adopts a more defined structure when interacting with activated FXIII-A2 or FXIIIA2B2 versus the FXIII-A2 analyzed.
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Once an aC (233 - 425) compact structure is defined, several different
heteronuclear methods will be used to assign the HSQC spectrum. TOCSy-15NHSQC can be run with a singly labeled 15N_ aC-domain. Further analysis could
be conducted with doubly labeled 13C_15N_ aC-(233 - 425). The benefit of the
doubly labeled protein is the ability to determine sequential residues using HNCO
and HN(CA)CO pulse sequences. For assigning more atoms in the amino acid
side chains, other 30 experiments such as: HNCA, HN(CO)CA, HN(CA)CB and
HN(COCA)CB can be used (131).
To determine the structure, NOE assignments could then be elucidated
using HSQC-NOESY, 15N_13C edited NOESY and 13C-13C-edited NOESY. The
residual dipolar couplings (ROCs) of the amide backbone could be determined
using 1H_ 15 N IPAP-HSQC with and without Pfl phage for spin alignment (102).
The NOE data gathered could then be entered into XPLOR-NIH (132) for
structural calculations using the angle restraints calculated by TALOS (133). It
would also be possible to determine the Kd of FXIII-A2 and aC(233 - 425) by
titrating in FXIII-A2 and monitoring the shift in resonances for the residues that
contact FXIII. TG2 could also be titrated in to determine if aC(233 - 425)
interacts with the two transglutaminases differently. This comparison would aid
in identifying differences in TG2 and FXIII substrate specificity.
These studies have shed light upon the illusive FXIII conformational
dynamics. This research presents a more global and functional understanding of
how FXIII interacts with substrates and allosteric effectors like Ca 2+ in solution.
These discoveries may lead to better control of FXIII-A2 activity during
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thrombosis and atherosclerosis through a more knowledgeable route of drug
discovery/design.
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APPENDIX A: A DETAILED DIAGRAM OUTLINING THE BLOOD
COAGULATION CASCADE
Kindly provided by Abeam pic, Cambridge, England
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Blood coagulation cascade

137

APPENDIX B: ABBREVIATIONS FOR BLOOD COAGULATION ENZYMES
Abbreviation
II
lIa
FV
FVa
FVII
FVlla
FVIII
FVllla
FIX
FIXa
FX
FXa
FXI
FXla
FXII
FXlla
FXIII
FXllla
vWF

Enzyme
Prothrombin
Thrombin
Factor V
Activated Factor V
Factor VII
Activated Factor VII
Factor VIII
Activated Factor VIII
Factor IX
Activated Factor IX
Factor X
Activated Factor X
Factor XI
Activated Factor XI
Factor XII
Activated Factor XII
Factor XIII
Activated Factor XIII
von Willebrand Factor
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APPENDIX C: FXIII-A2 PEPTIC PEPTIDES

Peptide
1-23
32-40
53-74
75-82
83-99
88-98
100-111
137-144
145-159
171-180
194-208
214-230
220-230
240-247
248-264
248-265
298-305
300-314
325-338
328-338
364-372
380-389
407-424
513-522
533-550
535-541
607-619
632-646
a

a

m/z
2431.30
926.15
2819.06
963.03
2188.48
1422.78
1509.78
1031.09
1682.03
1177.20
1930.10
2051.24
1372.70
1014.09
1713.97
1845.15
980.97
1800.83
1589.88
1217.36
1126.21
1133.28
1972.96
1198.55
2213.56
851.05
1534.65
1616.98

Amino Acid Sequence
SETSRTAFGGRRAVPPNNSNAAE
QGVVPRGVN
FKERWDTNKVDHHTDKYENNKL
IVRRGQSF
YVQIDFSRPYDPRRDLF
FSRPYDPRRDL
RVEYVIGRYPQE
REDRSVRL
SIQSSPKCIVG KFRM
RETSRNPETDT
YLDNEKEREEYVLND
YG EVNDI KTRSWSYGQF
IKTRSWSYGQF
YVMDRAQM
DLSGRGNPIKVSRVGSA
DLSGRGNPIKVSRVGSAM
ILLEYRSS
LEYRSSE NPVRYGQC
LRCLGIPARIVTNY
LGIPARIVTNY
PVPIVSELQSG
MTRPDLPVGF
YRCGPASVQAIKHGHVCF
KSRSNVDMDF
FKLSITFRNNSHNRYTIT
LSITFRN
FVTARINETRDVL
IIIKVRGTQVVGSDM

all m/z values represent the average mass of the undeuterated cluster.
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APPENDIX D: TG2 PEPTIC PEPTIDES

a

a

Peptide

m/z

12-25
26-39
31-39
154-160
237-253
259-269
315-329
341-353
369-377
451-461
452-461
475-487
502-508
547-554
560-568
668-686

2431.30
926.15
2819.06
963.03
2188.48
1422.78
1509.78
1031.09
1682.03
1177.20
1930.10
2051.24
1372.70
1014.09
1713.97
1845.15

Amino Acid Sequence
ELETNGRDHHTADL
CREKLWRRGQPFW
VVRRGQPFW
ERQEYVL
LGRWDNNYGDGVSPMSW
ILRRWKNHGCQ
FRNEFGEIQGDKSEM
MTRPDLQPGYEGW
CCGPVPVRA
EREAFTRANHL
REAFTRANHL
RIRVGQSMNMGSD
YVCRLLL
YEKYRDCL
IKVRALLVE
ESDKLKAVKG FRNVIIGPA

all m/z values represent the average mass of the undeuterated cluster.
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APPENDIX E: LB BROTH AND LB AGAR RECIPES

Table 1: 500 ml LB Broth
5.0 9 Tryptone
2.5 9 Yeast Extract
5.0 9 NaCI
Add 500 ml dH 20 and stir to mix. pH the solution to 7.5 with 10 M NaOH and
autoclave before use. If Ampicillin is needed, add prior to inoculation.
Table 2: 500 ml LB Agar
5.0 9 Tryptone
2.5 9 Yeast Extract
5.0 9 NaCI
7.5 9 Agar
Add 500 ml dH 20 and stir to mix. pH the solution to 7.5 with 10M NaOH and
autoclave. Let cool to -50°C and add 500 1-11100 mg/ml Ampicillin. Pour plates
and allow them to cool at room temperature. Cap and store at 4°C.
Table 3: 1 L SOB Medium
20.0 9
Tryptone
5.0 9
Yeast Extract
0.5 9
NaCI
Add 1 L dH 20 and autoclave. After the SOB solution has cooled, add 10 ml filter
sterilized 1 M MgCI2 and 10 ml filter sterilized 1 M MgS0 4 .
Table 4: 1 L SOC Medium (make immediately before use)
Add 2 ml filter sterilized 20 % glucose solution to 100 ml SOB Medium.
Table 5: 1 L Phosphate Buffer
KH 2 P04
23.2 9
164 9
K2HP0 4
Dilute to 1 L in volumetric flask. Transfer to autoclave safe bottle and autoclave.
Table 6: 2 L Terrific Broth
24.0 9
Tryptone
48.0 9
Yeast Extract
8 ml
Glycerol
Add 1.8 L of dH 20 and autoclave. Before use add 200 ml Phosphate Buffer.
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Appendix E (continued)
Table 7: 1 L E. coli Wash Buffer
20 ml
1 M Tris pH =8
10ml
5MNaGI
Dilute to 1 L with dH 20.
Table 8: 1 L Phosphate Buffered Saline (1 x PBS)
NaGI (137 mM)
8.0 9
0.2 9
KGI (2.7 mM)
Na2HP04 (10 mM)
1.42 9
0.24 9
KH 2P04 (2 mM)
187.5 9
glycerol (15 %)
Add 800 ml dH20 to the bottle and pH to 7.4 then fill to 1 L. Autoclave or filter
sterilize before use.
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APPENDIX F: NMR PEAKLIST FOR
assignment

15 N

ppm

1H

ppm

ac (233 - 425)

assignment

15 N

ppm

1H

ppm

112.288

7.488

41

122.081

8.541

2

129.646

10.131

42

121.855

8.256

3

129.613

10.099

43

121.761

8.393

4

129.416

10.075

44

121.775

8.061

5

129.358

10.147

45

121.583

8.226

6

126.523

8.409

46

121.534

8.26

7

125.876

8.3

47

121.481

8.337

8

125.794

8.415

48

121.481

8.29

9

125.606

8.387

49

121.333

8.438

10

125.449

7.883

50

121.342

8.359

11

124.919

8.207

51

121.318

7.916

12

124.547

8.346

52

121.199

8.262
8.554

13

124.393

8.177

53

121.146

14

124.24

8.254

54

121.162

8.128

15

124.107

8.292

55

121.097

8.5

16

123.979

8.386

56

120.978

8.316

17

123.884

8.416

57

120.813

8.15

18

123.734

8.577

58

120.78

8.472

19

123.634

8.253

59

120.731

8.52

20

123.542

8.494

60

120.724

7.854

21

123.342

8.164

61

120.724

7.844

22

123.266

8.313

62

120.653

8.262

23

123.229

8.437

63

120.49

8.443

24

123.136

8.705

64

120.328

8.564

25

123.073

8.402

65

119.935

8.095

26

123.113

8.366

66

119.712

8.166

27

122.928

8.721

67

119.491

8.036

28

122.916

8.195

68

119.439

8.434

29

122.867

8.237

69

119.189

8.263

30

122.794

8.482

70

119.113

8.402

31

122.801

8.271

71

118.949

8.366

32

122.685

8.216

72

118.892

8.316

33

122.661

8.443

73

118.813

8.403

34

122.608

8.327

74

118.825

8.35

35

122.566

8.6

75

118.781

8.29

36

122.527

8.373

76

118.655

8.472

37

122.358

8.298

77

118.56

8.501

38

122.309

8.245

78

118.49

8.399

39

122.262

8.577

79

118.085

8.223

40

122.183

8.465

80

118.056

8.296
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APPENDIX F (continued)
assignment

15 N

ppm

1H

ppm

assignment

15 N

ppm

1H

ppm

81

117.93

8.437

121

113.028

6.93

82

117.785

8.46

122

112.951

7.658

83

117.67

8.268

123

112.946

7.499

84

117.529

8.378

124

112.961

6.979

85

117.445

8.204

125

112.9

7.62

86

117.409

8.425

126

112.9

6.912

87

116.908

8.058

127

112.863

7.602

88

116.445

8.122

128

112.78

7.484

89

116.373

8.304

129

112.771

7.474

90

116.414

8.171

130

112.782

6.853

91

116.084

8.312

131

112.751

7.586

92

115.915

8.01

132

112.753

6.935

93

115.809

8.284

133

112.616

7.494

94

115.701

8.342

134

112.597

6.964

95

115.703

8.209

135

112.569

6.864

96

115.656

8.139

136

112.5

7.462

97

115.618

8.173

137

112.234

6.937

98

115.548

8.12

138

112.233

6.856

99

115.494

8.084

139

111.791

8.619

100

115.437

8.422

140

111.438

8.522

101

115.268

8.313

141

111.424

8.534

102

115.29

8.062

142

111.112

8.406

103

115.172

8.27

143

111.099

8.368

104

114.23

8.159

144

111.059

8.4

105

114.144

7.987

145

110.806

8.527

106

113.969

8.082

146

110.783

8.426

107

113.768

8.139

147

110.802

8.393

108

113.454

7.656

148

110.761

8.364

109

113.451

6.979

149

110.412

8.242

110

113.37

7.913

150

110.272

8.47

111

113.313

7.261

151

110.317

8.195

112

113.265

8.258

152

110.239

8.5

113

113.264

8.087

153

110.139

8.568

114

113.181

7.498

154

110.086

8.639

115

113.174

6.948

155

110.029

8.206

116

113.186

6.872

156

109.947

8.452

117

113.092

8.177

157

109.852

8.374

118

113.144

7.629

158

109.783

8.538

119

113.129

6.961

159

109.709

8.596

120

112.983

7.592

160

109.625

8.523
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APPENDIX F (continued)
assignment

15 N

ppm

1H ppm

161

108.948

8.506

162

108.918

8.472

163

108.909

8.334

164

108.823

8.358

165

108.815

8.446

166

107.949

8.267

167

107.658

8.205

168

132.122

8.078

169

119.788

8.254

170

113.171

7.322

171

112.27

7.589

172

129.965

10.091

173

110.822

8.569

174

110.805

8.669

175

110.651

8.637

176

115.748

8.46

177

115.782

8.262

178

121.697

8.432

179

121.084

8.644

180

121.578

8.608

181

122.942

8.325

182

113.242

7.19

183

113.396

7.694

184

129.669

10.078
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APPENDIX G: NMR ASSIGNMENTS FOR aC(233 - 425) IN THE PRESENCE
OF FXIII-A2
assignment

15 N

ppm

lH ppm

assignment

15 N

ppm

lH ppm

111.454

8.522

40

122.615

8.327

2

129.976

10.092

41

122.546

8.373

3

129.693

10.154

42

122.37

8.297

4

129.664

10.13

43

122.344

8.35

5

129.684

10.075

44

122.319

8.246

6

129.628

10.097

45

122.204

8.57

7

129.425

10.074

46

122.168

8.465

8

129.368

10.146

47

122.105

8.54

9

126.534

8.409

48

121.869

8.258

10

125.884

8.299

49

121.807

8.359

11

125.802

8.414

50

121.792

8.061

12

125.615

8.387

51

121.737

8.429

13

125.458

7.883

52

121.777

8.394

14

124.927

8.208

53

121.583

8.23

15

124.561

8.346

54

121.558

8.612

16

124.404

8.177

55

121.541

8.26

17

124.251

8.253

56

121.499

8.339

18

124.122

8.292

57

121.496

8.29

19

124.001

8.385

58

121.427

8.554

20

123.902

8.416

59

121.362

8.359

21

123.742

8.576

60

121.347

8.438

22

123.644

8.254

61

121.327

7.915
8.264

23

123.559

8.493

62

121.214

24

123.359

8.163

63

121.156

8.554

25

123.332

8.188

64

121.17

8.131

26

123.236

8.437

65

121.089

8.645

27

123.278

8.312

66

121.107

8.5

28

123.149

8.706

67

120.99

8.316

29

123.152

8.367

68

120.822

8.149

30

123.089

8.4

69

120.751

8.52

31

122.939

8.72

70

120.789

8.472

32

122.931

8.324

71

120.69

8.677

33

122.924

8.195

72

120.732

7.853
7.843

34

122.796

8.481

73

120.73

35

122.835

8.27

74

120.665

8.261

36

122.703

8.358

75

120.503

8.444

37

122.723

8.218

76

120.339

8.564

38

122.667

8.442

77

119.946

8.096

39

122.568

8.601

78

119.806

8.255
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APPENDIX G: (continued)
assignment

15 N

ppm

1H

ppm

assignment

15 N

ppm

1H

ppm

79

119.722

8.166

118

115.084

80

119.521

8.034

119

114.245

8.16

81

119.45

8.433

120

114.156

7.987

82

119.254

8.308

121

113.987

8.083

83

119.204

8.265

122

113.778

8.139

84

119.13

8.402

123

113.461

7.656

85

118.96

8.366

124

113.448

6.979

86

118.905

8.316

125

113.383

7.913
7.693

8.264

87

118.821

8.403

126

113.383

88

118.834

8.349

127

113.329

7.261

89

118.772

8.291

128

113.273

8.258

90

118.672

8.471

129

113.276

8.088
7.195

91

118.586

8.5

130

113.21

92

118.479

8.398

131

113.153

7.628

93

118.102

8.224

132

113.184

7.497

94

118.068

8.296

133

113.188

7.339

95

117.966

8.435

134

113.192

6.87

96

117.815

8.459

135

113.093

8.177

97

117.683

8.269

136

113.143

6.961

98

117.543

8.377

137

113.054

6.929

99

117.435

8.424

138

112.979

7.591

100

117.445

8.205

139

112.962

7.658

101

116.921

8.059

140

112.961

7.497

102

116.429

8.171

141

112.95

6.978

103

116.456

8.122

142

112.912

7.619

104

116.386

8.303

143

112.87

7.601

105

115.934

8.01

144

112.914

6.911

106

115.822

8.284

145

112.853

7.643

107

115.791

8.262

146

112.769

7.585

108

115.729

8.462

147

112.792

7.483

109

115.719

8.342

148

112.78

7.471

110

115.712

8.21

149

112.774

6.934

111

115.641

8.138

150

112.793

6.853

112

115.619

8.173

151

112.638

7.492

113

115.548

8.12

152

112.617

6.964

114

115.499

8.084

153

112.603

6.864

115

115.452

8.422

154

112.513

7.46

116

115.285

8.314

155

112.28

7.587

117

115.295

8.061

156

112.263

7.486
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APPENDIX G: (continued)
assignment

15 N

ppm

1H

ppm

157

112.236

6.937

158

112.247

6.855

159

111.803

8.618

160

111.438

8.534

161

111.1

8.405

162

111.111

8.367

163

110.832

8.585

164

110.818

8.569

165

110.817

8.527

166

110.823

8.393

167

110.811

8.672

168

110.793

8.425

169

110.771

8.363

170

110.654

8.64

171

110.423

8.242

172

110.324

8.194

173

110.289

8.47

174

110.258

8.5

175

110.167

8.568

176

110.102

8.639

177

110.033

8.206

178

109.955

8.451

179

109.861

8.374

180

109.792

8.537

181

109.725

8.596

182

109.61

8.522

183

108.952

8.506

184

108.918

8.471

185

108.928

8.334

186

108.827

8.446

187

108.843

8.358

188

107.952

8.266

189

107.669

8.204

190

113.158

6.947

191

132.113

8.077
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APPENDIX H: ABBREVIATIONS
(Not defined in coagulation schematic and in alphabetical order)
1D- One Dimensional
2D- Two Dimensional
a2AP- a2-antiplasmin
a-CHCA- a-cyano-4-hydroxycinnamic acid
AP- Activation Peptide
AUC- Analytical Ultracentrifugation
DMSO- Dimethylsulfoxide
DON- 6-diazo-5-oxo-norleucine
FXllla" a - Thrombin Activated FXIII
FXllla ca _ Calcium Activated FXIII
GDH- Glutamate Dehydrogenase
GDP- Guanine Diphosphate
GEE- Glycine ethyl ester
HDX- Hydrogen Deuterium Exchange
HSQC- Heteronuclear Single Quantum Coherence
IAA- lodoacetamide
IC50- Concentration Resulting in 50% Inhibition
IPAP- Inphase Antiphase
Kd- Dissociation Equilibrium Constant
MALDI- Matrix-Assisted Laser Desorption-Ionization
MS- Mass Spectrometry
MWCO- Molecular Weight Cut-Off
mlz- Mass to Charge ratio
NMR- Nuclear Magnetic Resonance
NADH- Nicotinamide adenine dinucleotide
TGase- Transglutaminase
TG2- Transglutaminase 2
TOF- Time-of-Flight
TOCSY- Total Correlation Spectroscopy
TFA- Trifluoroacetic acid
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